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ABSTRACT 
While most vaccine safety research has focused on acute adverse events, a 2013 Institute 
of Medicine report recommended observational studies on chronic, long-term outcomes 
following cumulative exposure to vaccines in early childhood. The Centers of Disease Control 
and Prevention’s Vaccine Safety Datalink (VSD) has initiated such research using electronic 
health record (EHR) and medical claims data from health plans nationwide; however, outcome 
misclassification has been cited as a major methodological challenge. Misclassification of 
clinical outcomes has garnered considerable attention in EHR-based research, with numerous 
studies validating algorithms for identifying outcomes in these data. However, there has been 
minimal attention given to using results from such validation studies to quantify and correct for 
bias of an exposure-outcome association caused by such misclassification.   
In this dissertation, simulations of VSD immunization schedule studies were developed to 
measure the magnitude of bias caused by outcome misclassification, and to test analytic solutions 
for this problem. The simulations’ results revealed that previous approaches, such as estimating 
overall outcome positive predictive values (PPVs), offer limited benefits for correcting bias (Aim 
1a), while quantitative bias analysis (QBA) methods are effective (Aim 1b).  For example, within 
a cohort of n= 257,010 children, simulations showed that Type 1 error rates of 100% occurred 
with outcome PPVs of 90% when differential outcome specificity was present. Since PPVs are 
the most commonly-reported estimate of algorithm validity, lesser-known bias analysis methods 
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using only predictive values were evaluated (Aim 2). These results revealed that outcome PPVs 
should be estimated by exposure, a departure from current practices in EHR-based research. 
Practical guidance was developed for integration of quantitative bias analysis within 
immunization schedule research (Aim 3), including demonstrating these methods within an 
example study of immunization schedule exposure and pediatric asthma. 
Bias from misclassification of clinical outcomes in EHR data is a long-recognized 
problem with underappreciated solutions. Failure to address outcome misclassification bias could 
lead to erroneous conclusions about the safety of the early childhood immunization schedule. 
The work presented in this dissertation challenges prevailing assumptions about the impact of 
EHR data misclassification, and establishes a foundation for implementing methodological 
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1.1       Background 
Following current recommendations by the U.S. Advisory Committee on 
Immunization Practices (ACIP), children receive up to 28 vaccinations against 14 diseases by 
their 2nd birthdays(1).  While the vast majority of parents choose to vaccinate their children 
per this recommended schedule, previous survey research has shown that 3 in 4 U.S. parents 
have concerns about the ACIP schedule (2).  Some parents worry that children receive too 
many vaccines at too young of an age and that vaccines cause chronic conditions(3). As a 
result, an increasing number of parents choose alternative immunization schedules where 
they delay or refuse some or all vaccines for their children.  Previous studies have estimated 
that 10-15% of U.S. parents choose to delay or refuse some vaccines for their children, and 
fewer than 1% of U.S. parents choose to not vaccinated their children at all(4-6).  A 2013 
Institute of Medicine (IOM) report concluded that while there is ample evidence supporting 
the safety of individual vaccinations, there is a need for observational research on whether 
the ACIP schedule as a whole is associated with risk of chronic outcomes, such as allergic 
and autoimmune conditions(7).  
The Centers for Disease Control and Prevention’s Vaccine Safety Datalink (VSD), 
which uses electronic health record (EHR) data from managed care organizations (MCOs) 
for vaccine safety research, has prioritized studies of the immunization schedule in its current 
research agenda(8). A key advantage of VSD data for studies of immunization schedule 
safety is the large sample size and power to detect even small differences in risk.  However, 
multiple sources of outcome misclassification in EHR data cause methodological concerns.  
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For example, miscoding by clinical providers, “rule-out” diagnoses, and coding for prevalent 
conditions can lead to false positive outcomes in EHR data, and use of health services not 
captured in the VSD database can cause false negative outcomes.   
While numerous studies have reported on misclassification in electronic database 
research(9-13), there has been limited work in quantifying the bias that arises from such 
misclassification and on methods for correcting this bias.  Previous studies have validated 
EHR-based algorithms for identifying several chronic outcomes of interest in immunization 
schedule safety research, including diabetes, asthma, and chronic urticaria(14-18).  However, 
these validated algorithms are not necessarily perfect algorithms: they typically have 
sensitivities, specificity, and predictive values less than 100%.    
To date, there has been a reliance on using overall misclassification metrics, 
particularly PPVs(13), to assess the potential for outcome misclassification bias in electronic 
data-based epidemiological research, without any empirical justification of this practice. 
More recently, quantitative bias analysis (QBA) has emerged as a field of methods for 
quantitatively accounting for bias caused by a number of sources, including 
misclassification(19).  However, there has been relatively slow uptake of QBA in 
epidemiological research, and very few applications in EHR-based research(20, 21). Barriers 
to implementation include under-appreciation for the amount of bias that can be caused by 
misclassification, low knowledge and utilization of quantitative bias analysis generally in 






1.2 Specific aims  
To address these barriers, the work presented in this dissertation aims to: 
Aim 1a: Evaluate whether outcome PPVs are effective indicators of outcome 
misclassification bias in simulations of electronic health record-based cohort studies of 
immunization schedule safety. 
Aim 1b:  Test the effectiveness of traditional methods for quantitative bias analysis 
using sensitivity and specificity estimates for outcome misclassification bias. 
Hypothesis 1: Quantitative bias analysis will correct risk ratio estimates observed 
with outcome misclassification to within 5% of the simulated (i.e., true) risk ratio. 
Aim 2:  Test the effectiveness of two predictive value-based methods for correcting 
bias of a risk ratio due to outcome misclassification: (a) a method requiring both PPVs and 
negative predictive values (NPVs) stratified by exposure, and (b) a method requiring only 
PPVs stratified by exposure, and assuming non-differential outcome sensitivity.  These 
approaches will be compared to analysis of electronic data as is, where any potential outcome 
misclassification is ignored. 
Hypothesis 2: The method requiring both PPVs and NPVs stratified by exposure will 
be most effective in correcting bias, as measured by the percent difference of the bias-
corrected risk ratio and the true risk ratio. 
Aim 3: Provide guidelines and recommendations for integrating quantitative bias 
analysis for outcome misclassification within electronic health record-based immunization 





 Vaccine safety studies receive immediate, intense public scrutiny, and the results of 
these studies can lead to major U.S. policy changes.  Failure to address outcome 
misclassification bias in current studies of immunization schedule safety could lead to 
erroneous conclusions about the safety of cumulative exposure to vaccines in early 
childhood. This results from this dissertation will inform researchers as to whether PPVs are 
effective indicators of outcome misclassification bias (Aim 1a), test the effectiveness of 
traditional QBA approaches using outcome sensitivity and specificity estimates and 
demonstrate their application (Aim 1b), test the effectiveness of predictive value-based QBA 
approaches and demonstrate their application (Aim 2), and provide researchers with practical 
guidance for implementing quantitative bias analysis in electronic health record-based 
immunization schedule research (Aim 3).  By investigating methods for quantifying bias that 
are most suited to EHR-based research, this dissertation will provide immunization schedule 













2.1 Vaccine safety in the United States 
The United States (U.S.) has a robust infrastructure for monitoring vaccine safety.  
Prior to licensing, vaccines undergo multi-phased clinical trials by the vaccine’s 
manufacturing company.  In these trials, vaccines’ safety and efficacy are first tested in 
animals, then in small groups of healthy humans, and finally in larger Phase III clinical trials.  
Since these Phase III trials are randomized, observed adverse events can be causally linked to 
the vaccine being tested(22).  Phase III vaccines trials are designed to test vaccine efficacy 
and short-term safety outcomes, and safety evaluations are usually limited to common, acute 
adverse events(22).   
After clinical trials are conducted, the Food and Drug Administration’s (FDA) Center 
for Biologics and Evaluation Research (CBER) is responsible for approving and licensing 
new vaccines in the U.S.  CBER’s vaccine licensing process involves a full review of safety 
and efficacy data from the clinical trials, a risk/benefit assessment, and an inspection of 
vaccine manufacturing facilities(23, 24).   Following licensure, CBER continues to regulate 
the vaccine product, and vaccine manufacturers are required to adhere to regular site 
inspections and quality reporting on each vaccine lot produced. For most new vaccines, 
CBER will also mandate that the vaccine manufacturer conduct post-marketing studies, 
referred to as Phase IV studies.  The goal of Phase IV research is to collect additional data on 
adverse events in larger cohorts of vaccine recipients, as well as to further assess the efficacy 
of the vaccine(23). 
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While the FDA is the main regulatory agency for vaccines in the U.S., the Centers for 
Disease Control and Prevention (CDC) plays an important role in monitoring vaccine safety 
following FDA licensure.  Specifically, CDC’s Immunization Safety Office (ISO) oversees 
three national vaccine safety monitoring programs:  the Vaccine Adverse Reporting System 
(VAERS, which is run jointly with the FDA), the Clinical Immunization Safety Assessment 
(CISA) project, and the Vaccine Safety Datalink (VSD). A fourth vaccine safety surveillance 
mechanism, the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) system, is 
run by the FDA. 
VAERS is a spontaneous surveillance system that has detected previously unknown 
vaccine adverse events, including intussusception following infant rotavirus vaccination(25). 
However, the lack of both denominator data and unvaccinated comparison groups makes 
conducting epidemiological investigations within this system challenging(26).  CISA’s focus 
is investigating vaccine adverse events at the individual patient level, including expert review 
of case reports and identification of patients at high risk of serious vaccine adverse 
events(27). FDA’s PRISM is the newest vaccine safety surveillance system in the U.S.  
Initiated in 2009 to provide rapid surveillance of a novel H1N1 influenza vaccine, it is now 
being expanded to other vaccine safety investigations(28).  In contrast, the VSD was initiated 
in 1995 and has a long history of conducting vigorous population-based surveillance and in-
depth epidemiological investigations of vaccine safety(29).  
2.1.a. Vaccine Safety Datalink 
The VSD is a collaborative effort between the CDC and managed care organizations 
(MCOs) nationwide.   As of 2017, seven U.S. MCOs were actively contributing data to VSD 
studies.  Using a distributed data model(30), participating MCOs pool their electronic health 
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record (EHR) data to conduct post-marketing surveillance and epidemiological studies of 
vaccine safety.  These EHR data represent over 10 million individuals, or approximately 3% 
of the U.S. 2010 population(29).  With this large population base, VSD studies are capable of 
identifying rare adverse events that smaller industry-led trials are typically underpowered to 
detect.  
 Historically, VSD studies have focused on individual or concomitantly administered 
vaccines and acute adverse events occurring in the days or weeks following immunization.  
VSD has identified previously unknown adverse events following vaccination.  For example, 
in 2010, VSD investigators found that 1-year-old children receiving ProQuad®,a newly-
licensed combined measles-mumps-rubella and varicella (MMRV) vaccine, had increased 
risk of febrile seizures 7-10 days following vaccination, as compared to children receiving 
measles-mumps-rubella (MMR) and varicella separately.  Through near real-time 
surveillance of newly-marketed vaccines and subsequent epidemiological investigation, VSD 
investigators determined that the combined MMRV vaccine led to 1 additional febrile seizure 
for every 2300 MMRV doses given, compared to giving MMR and varicella separately(31).  
Another notable VSD achievement was the investigation of intussusception following 
vaccination with Rotashield®, a rotavirus vaccine.   Following a signal identified in the 
VAERS spontaneous reporting system in 1999, VSD conducted an in-depth epidemiological 
study in participating MCOs, and found a 30-fold increase for intussusception 3-7 days after 
the first dose of rotavirus vaccination(32).  The Rotashield vaccine was subsequently pulled 
from the market(25). 
  While these examples of positive associations demonstrate VSD’s capabilities in 
conducting population-based vaccine safety research, VSD’s numerous negative studies also 
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have an important public health impact.  Most of the hundreds of studies conducted by VSD 
in the past 20 years have reported no association between the vaccine and adverse events 
studied(29).  Negative studies, or those finding no association between vaccines and adverse 
health outcomes, are critically important in reassuring the medical community and the public 
at large about the safety of immunization as a public health interventions(33). 
2.1.b. Methodological challenges in studies of acute outcomes following vaccination 
VSD’s success has been tied to its ability to address methodological issues in safety 
studies of acute adverse events following vaccination.  Two major methodological concerns 
in this line of research are data misclassification and unmeasured confounding.  Data 
misclassification occurs when algorithms for identifying exposures and outcomes in EHR 
data have imperfect sensitivity or specificity.   Unmeasured confounding is also an issue, 
since not all covariates desired for an epidemiological investigation may be in EHR data as 
part of routine clinical practice.  Previous studies have shown that the minority of parents 
who choose to delay or refuse some or all vaccines for their children differ from parents who 
vaccinate their children per the recommended schedule with regard to income, education, and 
other factors that are often not routinely captured in EHR data(34, 35).  
The application of novel study designs such as the self-controlled case series (SCCS) 
have allowed VSD to largely circumvent the issues of unmeasured confounding and 
misclassification in EHR data.  In a SCCS design, only vaccinated individuals who 
experience the outcome of interest are included in analysis.   The analysis of this case-only 
approach relies on comparing the incidence rate of the outcome in a pre-specified risk 
window following vaccination to the incidence rate in a control period not related to 
vaccination.  In the design, individuals’ risk and control windows are considered to be 
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matched, and a conditional Poisson model is applied.  Using this statistical framework, all 
fixed unmeasured covariates are implicitly controlled for by design(36).  The SCCS design 
has been shown to perform comparably to traditional cohort and case-control designs in 
terms of statistical power and providing unbiased estimates of risk(37).   
Along with controlling for fixed unmeasured confounding, another important strength 
of the SCCS design in VSD research has been the limited number of cases that are detected 
in analysis.  When studying acute adverse events, risk periods are usually limited to days or 
weeks following vaccination.   Control windows not following vaccination may be the same 
length or may be as long as several months.  By only looking for outcomes during these short 
pre-specified windows, the number of events observed in a SCCS design is typically much 
smaller than what would be observed in a cohort study(37).   As a result, VSD study teams 
are often able to confirm outcomes in a SCCS study through review of clinical notes in 
patients’ medical record and an adjudication led by clinical experts(30).   After review, data 
are re-analyzed with only the confirmed cases.  The ability to perform these structured chart 
reviews is an advantage of VSD’s work in U.S. vaccine safety surveillance, as it minimizes 
the potential for outcome misclassification in such case-only VSD studies of acute outcomes 
following vaccination. 
2.1.c.  New Vaccine Safety Datalink initiatives 
Since its inception 20 years ago, the VSD has primarily focused on rapid surveillance 
and epidemiological investigations on the safety of newly licensed vaccines, seasonal 
influenza vaccinations, and new vaccination recommendations to broader populations, such 
as expanded influenza vaccination recommendations and vaccines now recommended during 
pregnancy(30,38). Examining vaccine safety in other special sub-populations, such as 
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children with chronic medical conditions, is another area of vaccine safety research(39).  
Lastly, while VSD studies have traditionally focused on the safety of individual vaccines, 
there is now increased interest in studying the safety of cumulative exposure to vaccines(7, 
40). In particular, VSD has recently prioritized research on the safety of the early childhood 
immunization schedule recommended by the Advisory Committee on Immunization 
Practices(7). 
2.2  The U.S. recommended immunization schedule 
Established in 1964 by the Surgeon General of the Public Health Service, the 
Advisory Committee on Immunization Practices (ACIP) develops immunization policy 
recommendations in the U.S(41).  The voting members of the ACIP are elected experts in 
vaccinology, infectious diseases, immunology and pediatrics, along with one consumer 
representative.  Non-voting members include participants from government agencies and 
other medical organizations(41).  
After new vaccines are licensed by the FDA, ACIP determines whether the vaccine 
should be incorporated into the recommended immunization schedule in the U.S.    When 
ACIP started its work in the 1960s, vaccines against six infectious diseases (diphtheria, 
measles, pertussis, polio, smallpox, and tetanus) were available and routinely recommended 
to children(41).   As shown in Appendix A, as of the 2017 ACIP schedule, children are 
recommended to receive between 20 and 28 vaccines against 14 diseases by their 2nd 
birthday(1).   Appendix B shows a timeline of major changes and additions to this schedule 
between 1983 and 2017.  The changes ACIP has made to the U.S. pediatric immunization 
schedule fall into four broad categories:  adding new vaccines to the schedule following FDA 
approval, approving the use of new combination vaccines (i.e. two or more already-approved 
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individual vaccines combined in the same injection) in the immunization schedule, 
expanding recommendations to include broader groups of children, and removal of vaccines 
from the schedule due to safety concerns.   
2.2.a.  Immunization schedule considerations 
ACIP uses several criteria to determine the optimal timing and spacing of early 
childhood vaccinations(7).  The first criterion is vulnerability to disease.  Since the goal of 
vaccination is to provide immunity against disease, vaccines are ideally administered to 
children before they are at risk of the targeted disease.  Passive transfer of immunoglobulin G 
(IgG) from mother to child offers protection against some infectious diseases.  Once these 
maternal antibody levels decline, immunizations offer infants the opportunity to create their 
own immune responses to vaccine antigens.  These IgG antibodies then protect the child if 
they are later exposed to the disease(7).   
A second criterion for determining placement of vaccine on the ACIP schedule is the 
demonstrated efficacy of the vaccine at various ages.  During pre-approval testing, vaccine 
manufacturers seek to determine the “biologically optimal”(7) time that children should 
receive vaccines.  Ideally, vaccines are given when they are safest and most effective.  
Vaccine efficacy at various ages is influenced by the type of vaccine.  For example, passive 
maternal antibodies to measles can be present in children for up to 12 months, and these 
antibodies decrease the child’s antibody response to the live virus MMR vaccine(42).   
Therefore, the MMR vaccine is recommended to children after age 12 months.  Other 
vaccines, including the inactivated diphtheria-tetanus-acellular pertussis (DTaP), 
Haemophilus influenza type b (Hib), and pneumococcal conjugate (PCV) vaccines, have 
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shown to be effective as early as six weeks of age, and are therefore recommended starting at 
this age. 
A final consideration for incorporating a new vaccine into the U.S. recommended 
schedule is feasibility and logistics(7).  Starting in 1995, the ACIP and the American 
Academy of Pediatrics (AAP) sought to synchronize the recommended U.S. pediatric 
immunization schedule with the AAP’s recommended well-child visit schedule(43). Once the 
ideal age range for vaccination is established, vaccines in pre-licensure trials are typically 
tested at the recommended ages for well child visits and with other vaccines given at those 
same visits. The AAP recommends well child visits at birth, age 1-2 weeks, and ages 2,4,6,12 
and 18 months, with optional visits at ages 9 and 15 months(43).    
2.2.b.  Universal immunization as a major public health achievement 
Universal recommendation of early childhood vaccines through a unified schedule 
has been hailed as one of the top public health achievements in the U.S. (44, 45). It has been 
estimated that for children born in 1994-2013, vaccination per the ACIP schedule prevented 
over 700,000 deaths and 21 million hospitalizations(45, 46). There are several remarkable 
examples of the success of vaccines in prevention of serious infectious diseases in young 
children(45).  Introduction of the pneumococcal vaccine to the early childhood immunization 
schedule has prevented an estimated 13,000 deaths and 211,000 infections in 2000-2008(45, 
47).  In the first three years following reintroduction of the rotavirus vaccine in 2006, the 
U.S. experienced a reduction of between 40,000 and 60,000 rotavirus hospitalizations 
annually(45, 48).   
Measles elimination was declared in the U.S. in 2000, meaning that the disease was 
no longer considered endemic(49, 50).  In the ten years after measles elimination in the U.S., 
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there was a median of 60 cases per year(50).  However, the median number of cases per year 
jumped to 205 in 2011-2014(50).  Highly publicized measles outbreaks included one 
stemming from an unvaccinated child visiting Disneyland in Orange County, California, 
which led to 125 measles cases identified between December 28, 2014 and February 8, 2015 
(51, 52).  Approximately one quarter of the measles cases tied to this outbreak were 
individuals who were unvaccinated due to individual or parental choice(51). 
2.2.c.  Vaccine hesitancy, under-vaccination, and alternative immunization schedules 
 It is often said that vaccines are “victims of their own success”(53).  Given the 
effectiveness of vaccines in controlling and eliminating infectious diseases, parents are often 
unfamiliar with vaccine-preventable diseases in childhood(53).  Since the risk of disease is 
not apparent, some parents become more concerned with potential vaccine side effects than 
with disease risk to un- or under-vaccinated children(53, 54).  The term vaccine hesitancy has 
been used to encompass a broad range of concerns and actions regarding vaccines(53, 55).   
While most vaccine hesitant parents will choose to vaccinate their child per the ACIP 
schedule(53), some choose to withhold some or all vaccines, delay some or all vaccines until 
a later age, or space out their child’s vaccines differently than the ACIP schedule. 
 Some parents who refuse or delay vaccines believe that their child will be protected 
from these diseases due to herd immunity(56).  Herd immunity refers to population-level 
immunity that is conferred against a disease above and beyond an individual’s immunity and 
vaccine coverage in the population(57).  In other words, the higher the prevalence of disease 
immunity in a community, the more difficult it is for any one person in that community to get 
the disease, even if he/she is not immune.  However, the level of herd immunity necessary to 
prevent vaccine-preventable disease transmission is often difficult to measure(57).  Despite 
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high vaccine coverage levels in the U.S.(58), a series of studies in Colorado demonstrated 
that parents should not rely on herd immunity, as vaccine hesitancy is associated with 
increased vaccine-preventable disease risk.  In these studies, children whose parents refused 
vaccines experienced a 19-fold increased risk for pertussis, an 8-fold increased risk for 
varicella, and a 6-fold increased risk for pneumococcal disease as compared to children 
whose parents permit these vaccines for their children (59-61).  Simply being behind on 
recommended doses of pertussis-containing vaccines is also associated with increased risk of 
pertussis as compared to getting all doses on-time(62).   
2.2.d.  Prevalence of vaccine hesitancy and under-vaccination in the U.S. 
 The prevalence of parental vaccine hesitancy and under-vaccination in the U.S. can 
be assessed with several data sources(53).  A 2010 nationally-representative mailed survey of 
n=376 U.S. parents of children ages 6 years and younger found that 2% U.S. parents declined 
all vaccines for their children, and additional 5% declined some vaccines(3).  While the vast 
majority of parents accepted all recommended vaccines for their children, 77% of parents 
reported having concerns about childhood vaccines.  Specific concerns cited by parents are 
that children receive too many vaccines at one time (36% of parents), children get too many 
vaccines before age 2 years (34%),  vaccines contain harmful ingredients (26%), and 
vaccines may lead to chronic conditions later in childhood (16%)(3).  A larger data source for 
assessing national vaccine coverage is the CDC’s National Immunization Survey (NIS), 
which is an annual survey of parents of children ages 19 to 35 months.  The 2012 NIS 
collected medical provider-confirmed immunization data on n=16,916 children, and found 
that 31.6% (+- 1.4%) of children were missing at least one dose of DTaP, poliovirus, Hib, 
HepB, pneumococcal conjugate, MMR or varicella vaccines(58).  More recently, the 2016 
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NIS survey of n=14,988 U.S. children reported that 0.8% (95% confidence interval: 0.6% - 
1.0%) had not received any vaccines by age 19-35 months(6).  
In contrast to the cross-sectional NIS vaccine coverage metrics, re-analysis of 2012 
NIS data by Kurosky et al. using a longitudinal approach showed that 73% of children were 
actually late for at least one vaccine dose at some point before age 24 months(63).  Similarly, 
Glanz et al. analyzed electronic medical records from n=323,247 children at six managed 
care organizations (MCOs) nationwide and found that almost half were late for a 
recommended vaccine at some point before age 24 months(5).  
While parental vaccine hesitancy is a contributing factor to the levels of under-
vaccination observed in the studies by Kurosky et al.(63) and Glanz et al.(5), there are many 
other causes for being late or missing vaccine doses.  Other reasons for under-vaccination in 
young children includes barriers to receive care, such as transportation to appointments, and 
financial cost(5).  However, it is likely that children in managed care insurance plans, which 
was the setting for the Glanz et al. study, have fewer financial barriers to vaccination as 
compared to the general public due to vaccines being available for little or no cost. 
2.2.e. Alternative immunization schedules 
The differences in the percent of young children who are under-vaccinated at any 
point before their 2nd birthday and the coverage metrics produced by the NIS can be partially 
explained by parents who are choosing alternative vaccination schedules for their children.   
A 2010 online survey of n=748 parents of children under age 6 years found that 13% chose 
an alternative immunization schedule for their children, including delaying the start of some 
or all vaccines, adding additional time between doses, or limiting the number of vaccines 
16 
 
given per immunization visit.   Among parents choosing an alternative schedule, 82% 
believed that delaying vaccines is safer than the ACIP schedule(4).  
Some of the public interest in alternative immunization schedules can be credited to 
the publication of The Vaccine Book, by Dr. Robert Sears, a pediatrician practicing in 
Orange County, CA(64).  In this book, which was published in 2007 and has sold over 
250,000 copies(65), Dr. Sears purports to offer an unbiased, personal look at the risk and 
benefits of each childhood vaccine.  He offers parents two alternative immunization schedule 
options that do not align with ACIP’s and AAP’s recommendations.   His “Alternative 
Schedule” involves spacing out vaccines in the first two years of life so that the child is 
eventually caught up with all vaccines per the ACIP schedule, but only receives two or fewer 
vaccines per visit. His “Selective Schedule” involves withholding some vaccines altogether, 
including polio and MMR, as Dr. Sears deems these to be unimportant and to have 
potentially risky side effects(64).  There are several issues in Dr. Sears’ book, including how 
the risk of vaccine-preventable diseases is downplayed and suggestions that un- or under-
vaccinated children will likely be protected by herd immunity(66).    
Despite these issues, the book has had broad popular appeal. An analysis of MCO 
records found that the number of children appearing to follow his “Alternative Schedule” 
jumped from about 20 per 10,000 children born in 2007 to over 100 per 10,000 children born 
in 2008(67). An analysis of Oregon state immunization registry data showed that the 
percentage of consistent shot-limiters, defined as parents who limit the number of vaccines 
given per visit to two or less, increased from 2.5% in 2006 to 9.5% in 2009(68). In addition, 
a national survey of physicians in 2009 found that 89% reported that they receive at least one 
request a month from parents to spread out their child’s vaccines, and that 20% reported that 
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over 10% of the parents they see in a typical month requests to spread out their child’s 
vaccines(69). 
In The Vaccine Book, Dr. Sears states that spacing vaccines is necessary for two 
reasons: to avoid overloading the immune system and to prevent potential negative effects of 
exposure to aluminum adjuvants in vaccines(64).  While neither of these claims are 
supported by current scientific evidence(66), the public’s questioning of the ACIP schedule 
has led to increased interest by the medical and scientific community in further investigating 
the safety of the immunization schedule as an entity(7, 70, 71).  In response to growing 
vaccine hesitancy, increased adoption of alternative schedules, and several highly publicized 
vaccine-preventable disease outbreaks, in 2012 the Institute of Medicine convened a 
committee to study immunization schedule safety. The 14-person committee of medical and 
public health experts was charged with reviewing existing research on immunization 
schedule safety, engaging a range of stakeholders, and recommending future studies on the 
safety of the U.S. recommended immunization schedule(7).   
2.2.f. Institute of Medicine report on immunization schedule safety 
 The IOM committee’s 2013 report, titled Childhood Immunization Schedule and 
Safety:  Stakeholder Concerns, Scientific Evidence and Future Studies, summarized current 
evidence on the safety of the ACIP schedule and established an agenda for future research on 
the safety of the early childhood immunization schedule in the U.S.(7).  While most vaccine 
safety research in the U.S. has historically focused on acute outcomes, the committee sought 
to understand existing evidence surrounding the safety of the immunization schedule with 
regard to risk of future long-term outcomes.  In their review of current scientific evidence on 
the safety of the immunization schedule, the IOM committee focused on four groups of 
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chronic outcomes:  allergy and asthma, autoimmune diseases, autism and other 
neurodevelopmental disorders, and seizures, febrile seizures, and epilepsy.  The committee 
conducted a literature review of studies with these outcomes where a component of the 
immunization schedule was the exposure of interest.  Such exposures included the 
cumulative number of vaccines received, frequency of vaccine administration, the spacing of 
vaccine doses, age of vaccine recipient and order of vaccines given(7).  The committee 
concluded that there has been limited research on the overall immunization schedule and 
these outcomes.  While any available evidence was reassuring, the committee called for 
additional research on early childhood immunization schedule safety(7). 
In the report, the IOM committee also described the process for determining the U.S. 
immunization schedule, reviewed existing data sources for conducting research on 
immunization schedule safety, and engaged stakeholders, including concerned parents and 
vaccine advocacy groups, to document their safety concerns.  In summary, the IOM 
concluded that while there is ample research supporting the safety of individual vaccines, 
more research is needed on the safety of the immunization schedule as whole.  The IOM 
outlined four leading research questions.   Three of the research questions focus on 
examining long- and short-term health outcomes in children who receive no vaccines, 
children who receive some but not all recommended vaccines, and children who have their 
vaccines spaced out, all compared to children who receive vaccines on-time per the ACIP 
schedule.  An additional research question proposed by the committee involves studying the 
association between immunization schedule exposure and long-term outcomes in susceptible 




The IOM committee further concluded that randomized controlled trials of 
immunization schedule safety would be unethical, since it would put some children at 
increased risk of contracting vaccine-preventable diseases.  The committee said that such 
research would need to rely on observational data, and that the VSD, with its large EHR 
database, would be the ideal setting for these studies(7).  Subsequently, the CDC 
commissioned the development of a white paper to address how such research could feasibly 
be conducted in VSD.  The White Paper on Studying the Safety of the Childhood 
Immunization Schedule in the Vaccine Safety Datalink (“White Paper”) outlined strategies 
for defining exposure to an early childhood immunization schedule, prioritized outcomes for 
VSD to study, and described methodological approaches to studying immunization schedule 
safety(40).  However, as described in the White Paper, there are many opportunities for bias 
in EHR-based studies of immunization schedule safety.  In particular, issues with 
measurement error, specifically misclassification of outcomes, pose significant 
methodological challenges in studies of the early childhood immunization schedule using 
EHR data.   
2.3  Misclassification in electronic health record-based research 
Misclassification refers to incorrect measurement of a binary variable, such as 
presence or absence of a disease (72).  Bias from imperfect measurement of important 
variables has been one of the most studied methodological issues in epidemiological research 
(72-80).  To date, most attempts to address this issue center on reducing the magnitude of 
misclassification for a given variable.  However, epidemiologists have warned that even 
small amounts of misclassification can have “profound” impacts in the estimation of an 
exposure-disease association (72).  
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Large EHR databases are increasingly being relied upon for post-marketing research 
of drugs and vaccines(81).  These data are collected as part of routine medical encounters and 
are not collected for the purposes of conducting research. The primary advantage of EHR-
based studies is their large sample size, which permit the detection of rare outcomes.  These 
studies are conducted more quickly and with fewer resources than studies relying solely on 
primary data collection(81).  However, within these large databases, the ability to perfectly 
discriminate between individuals with and without a clinical condition is limited, if not 
impossible.    
Within EHR-based research, algorithms are developed and applied to the electronic 
data to distinguish people with and without a condition of interest.  A range of structured data 
variables may be available in EHR databases to inform these algorithms, including 
International Classification of Diseases (ICD) codes, Current Procedural Terminology (CPT) 
codes, pharmacy dispensings, immunization records and laboratory tests and results(82).  
Such EHR-based algorithms have also been referred to as “computable phenotypes” in the 
literature (83, 84). Documentation from medical providers may also be available, but these 
data are typically unstructured and less readily useable using standard database management 
systems and analytic techniques(82).   
Manual review of these clinical notes (often referred to as “chart reviews”) can be 
used to extract information from these unstructured clinical provider notes in EHRs(85). 
Chart reviews have been readily used in VSD studies of acute adverse events, and allow 
researchers to confirm whether the outcomes identified in electronic data represent true, 
incident cases of the vaccine adverse event of interest.  While such a process may help avoid 
some issues relating to data misclassification, these processes involve substantial human, 
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time, and financial resources above that of electronic-only analyses(85).  Moreover, while 
chart review can help distinguish true positives from false positives in electronic data, it does 
not always provide reliable methods for identifying false negatives, or for calculating the 
sensitivity and specificity of algorithms used to identify clinical outcomes in electronic data. 
The metrics of sensitivity, specificity, positive predictive values, and negative 
predictive values are used to describe the magnitude of misclassification of a given variable.   
Table 1 shows how these metrics can be applied to understanding outcome misclassification 
in EHR data.   Table 2 shows the calculations for sensitivity, specificity, positive predictive 
values, and negative predictive values(86). Outcome false positives can occur for many 
reasons, including misdiagnosis, coding of a rule-out diagnosis on a patient’s chart, or coding 
for a prevalent condition. Outcome false negatives could occur, for example, if a condition is 
not acute or severe, since parents will vary in their likelihood of bringing a child in for care 
for such conditions.  Outcome false negatives could also occur if some parents choose to seek 
care for their children in non-traditional settings, such as with complementary medical 
providers (e.g. chiropractors or naturopathic providers)(87).  Miscoding, which is an 
incorrect application of a diagnosis or procedure code to a medical record, can lead to both 
outcome false positives and false negatives. In addition, coding for conditions with known 
etiologies (for example, a diagnosis code for a seizure in a risk period following vaccination 
in a child with a documented chronic seizure condition) can also cause issues when trying to 
use electronic health data to ascertain specific exposure-outcome associations. 
A fundamental component of VSD studies of acute adverse events has been 
structured manual reviews of clinical notes to validate EHR-based outcome identification 
algorithms. The results of these chart reviews have clearly demonstrated the problem of 
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misclassification in EHR data (30, 88, 89).  Table 3 lists reasons for outcome 
misclassification and supporting examples from vaccine research using electronic databases.  
For example, in a VSD review of ICD, 9th edition, clinical modification (ICD-9-CM) codes 
for febrile seizures in the emergency department setting, 97% were confirmed to be incident 
febrile seizures(90).  In contrast, only 7% of patients in VSD databases identified to have 
anaphylaxis using EHR-based algorithms were confirmed to have incident anaphylaxis after 
review of medical records(91).  In another VSD study, a review of clinical notes for n=7 
cases of electronically-coded hypotension (low blood pressure) in children ages 24 to 59 
months revealed that one was a case of hypertension (high blood pressure), and two were 
cases of children who had accidentally ingested antihypertensive medications(92) 
In 2015, Lanes and colleagues described a framework for developing and evaluating 
EHR-based outcome identification algorithms(12) (Table 4).  In particular, outcome 
identification in EHR data is likely to have highest validity when the outcome has an 
objective clinical presentation and is severe enough that the vast majority of patients will 
seek medical attention for such conditions.  The ideal database for identifying outcomes 
would have complete medical records on participants and the database would undergo 
regular quality assessments.  In addition, Lanes and colleagues encourage conducting 
outcome validation studies, and using the results from such studies to estimate the magnitude 
of misclassification bias(12). 
As these challenges in outcome ascertainment within electronic data-based 
epidemiological research have become more evident, outcome validation studies have 
become more prevalent.  In one type of validation study, researchers test the performance of 
electronic database algorithms against existing diseased and non-diseased cohorts, and 
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estimate the outcome’s sensitivity and specificity.  More commonly, researchers estimate 
positive predictive values (PPVs) by reviewing clinical notes on a sample of individuals 
observed to have the outcome, and calculate the percentage of observed outcomes that are 
true positive outcomes.  PPVs are the most commonly reported measure of outcome 
algorithm validity in electronic database research(13).   In contrast, negative predictive 
values (NPVs) are the least-reported measure of algorithm validity(13).  For some outcomes, 
estimating NPVs can be quite challenging, or nearly impossible.  This is because NPV 
estimation in electronic data involves sampling from a very large group of individuals 
observed not to have the outcome, and then distinguishing who does and does not have the 
outcome in this group.  Since outcome false negatives are often caused by outside use of 
health services, identifying false negatives through standard approaches, like review of 
clinical provider notes, may not be fruitful. Estimation of NPVs in electronic data is 
particularly difficult with rare outcomes. 
A priority list of clinical outcomes has been established for VSD immunization 
schedule safety research.  Table 5 shows estimates of sensitivity, specificity, PPV, or NPV 
that have been published for select outcomes.  The values of metrics vary widely, from a 
6.8% PPV for identifying anaphylaxis in the outpatient setting to specificity greater than or 
equal to 99.8% for identifying pediatric diabetes in EHR data.  As pointed out by Lanes and 
colleagues in the framework shown in Table 4, these validation studies are promising 
because they provide information as to the extent of misclassification of these outcomes in 
electronic data. Currently, many EHR-based studies cite the use of such validated algorithms, 
without making use of any information provided from the validation studies.  While some 
validation studies report high levels of sensitivity, specificity, or predictive values, these 
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studies typically provide some information as to the presence of and reasons for false 
positives and false negatives in the data.  Such misclassification can lead to bias, yet this 
information bias is rarely quantified in EHR-based research. 
2.3.a. Information bias 
When estimating an exposure-disease association, there are two types of error: 
random error, which is influenced by a study’s sample size, and systematic error, which 
refers to flaws in the study’s design or conduct(19).  While random error affects the precision 
of an exposure-disease estimate, systematic error refers to bias of the estimate itself.  Often, 
EHR-based studies have large sample sizes, and the low random error is quantified with 
narrow confidence intervals.  However, most observational studies are also affected by 
systematic error from information bias, unmeasured confounding, or selection bias(72).  
Measurement error refers to information bias caused by imperfect measurement of variables 
used in an analysis.   
Figure 1 provides a graphical representation of the implications of systematic and 
random error.  Similar graphical representations have been used elsewhere in social science 
and epidemiological instruction(93).  For this example, the true risk ratio (RR) representing 
an association between an exposure and disease is 2.00.  In other words, individuals with the 
exposure truly have a 2-fold greater risk of disease.  An epidemiological study of this 
exposure-disease relationship reporting a RR of 2.00 with a 95% confidence interval (CI) of 
0.95-3.05 has low systematic error, but high random error (Figure 1a).  An epidemiological 
study observing a RR of 1.00 would have high systematic error, since 1.00 is a biased 
estimate of the true RR of 2.00 (Figure 1b).  However, if that study reported a 95% CI of 
0.95-1.05, it would have low random error. Finally, as shown in Figure 1c, a study reporting 
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an RR of 2.00 with a 95% confidence interval of 1.95-2.05 with have both low systematic 
and random error. 
2.3.b. Human reasoning under uncertainty 
Systematic error is rarely quantified in EHR-based research(21).  Instead, qualitative 
assumptions as to the potential impact of misclassification are commonplace(19, 94).  How 
humans make assessments in the face of uncertainty has long been a topic of interest in 
psychology(95), and psychologists have found that most people, regardless of educational 
background, make predictable errors in judgement when dealing with unknown factors(96).  
Two approaches that researchers commonly employ for dealing with misclassification 
highlight flaws in human reasoning.  
First, there is a tendency to believe that overall metrics of misclassification 
(sensitivity, specificity, PPVs, or NPVs) can be used to gauge the presence or absence of bias 
of an exposure-outcome association.  These metrics do describe the performance of an 
outcome algorithm and the degree to which it does or does not identify true outcomes in 
electronic data(12).  However, it is unclear whether the values of these metrics alone provide 
sufficient evidence as to any bias caused by using the algorithm to estimate an exposure-
outcome association. 
For example, in electronic database research, overall outcome PPVs are the most 
common measure of algorithm validity, and it has been previously proposed that outcome 
PPVs greater than 70% are sufficient for data-only analysis(11).  However, since predictive 
values are a function of a variable’s sensitivity, specificity, and prevalence (see Appendix C 
for Bayes’ Rule describing these relationships), the values of PPV can vary widely based on 
any one of these factors.  Furthermore, PPVs provide no information as to the existence of 
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false negatives.  There has been limited work in quantifying whether qualitative judgements 
as to the presence of bias based on overall misclassification metrics are correct, and whether 
overall outcomes PPVs are appropriate indicators of bias of an exposure-outcome 
association.  
Second, researchers commonly assume that if misclassification bias is present, such 
bias is toward the null.  Misclassification is often acknowledged in research paper’s 
discussion section, and researchers sometimes conclude that if there is misclassification, it is 
likely non-differential.  With non-differential outcome misclassification, outcome sensitivity 
and specificity is equal between exposed and unexposed participants.   If non-differential 
misclassification is present in a study, and the observed results lead to rejection of the null 
hypothesis, then the typical conclusion is that the true effect is actually greater than the 
observed effect and thus the misclassification is inconsequential(86).   
There are three problems with assuming bias to the null from non-differential 
misclassification of either exposure or outcome in EHR-based studies of the early childhood 
immunization schedule.  The first problem is the tenuous assumption non-differential 
outcome misclassification.  Previous EHR-based research suggests that children who are 
undervaccinated have different patterns of healthcare utilization than children who get 
vaccines on-time, and tend to use fewer outpatient services(5).  Parents who delay or refuse 
vaccinations have also been shown to take their children to complementary medicine 
providers more often that parents who choose to follow the U.S. recommended immunization 
schedule(87). If parents of undervaccinated children are using services outside their MCO, 
then an EHR-based system may miss clinical outcome data for that population. Each of these 
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situations would lead to differential outcome misclassification in a study of immunization 
schedule safety. 
The second problem with assuming bias to the null from non-differential 
misclassification is that, even if the strict criteria to meet this assumption are met, bias to the 
null is not guaranteed.  The assumption of bias to the null from non-differential 
misclassification only holds with a binary outcome.  Bias can be toward or away from the 
null with multi-level or continuous variables(77, 80, 86).  Also, while on average, a non-
differential misclassification process will produce bias to the null, random variation can lead 
to differential misclassification, and thus bias toward or away from the null, in a given study.  
This phenomenon has been empirically shown through simulation(74, 86).   Moreover, there 
is one presentation of outcome misclassification that causes no bias of a ratio measure.  If an 
outcome has perfect specificity (i.e. no outcome false positives) and imperfect sensitivity that 
is non-differential to exposure, then there is no bias of a risk ratio(86).  However, difference 
measures, such as an attributable risk, can be biased in this scenario(86).   
The third and most important problem for assuming bias to the null in a study of the 
early childhood immunization schedule is how to then interpret an observed null finding.  If 
data misclassification is a concern, but the assumption is that such misclassification will bias 
results to the null, then there is potential to commit Type II error, or failing to reject the null 
hypothesis when the alternative hypothesis is true.  Studies of the early childhood 
immunization schedule should seek to reassure parents, physicians, and the medical 
community about the safety of early childhood vaccines. The potential for a Type II error 
from non-differential misclassification would result in spurious conclusions about 
immunization schedule safety.  
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ACIP has changed national immunization recommendations based on results from 
past VSD observational studies, and studies of immunization schedule safety may have 
immediate policy implications. Moreover, immunization schedule safety research has 
garnered attention from concerned parents(7), and these studies’ results will be scrutinized in 
the public arena.  Therefore, it is imperative that methodological challenges that would lead 
to estimation of a biased immunization schedule-outcome association are proactively 
addressed. Quantitative methods for measuring the impact of misclassification bias are 
needed to address such challenges.  
2.3.c.  Quantitative bias analysis 
Quantitative bias analysis (QBA) refers to a field of analytic methods for quantifying 
systematic error, including misclassification, in epidemiological research.  QBA 
encompasses a broad range of approaches in assessing how far an observed effect is from the 
true effect given known information about the levels of misclassification in the data (19).  
These methods are most useful when a study has low random error and when there are 
limited, known sources of systematic error(19).   Large studies, such as EHR-based studies, 
that yield precise observed results are favorable to bias analyses since random error is 
minimal.  Limited sources of systematic error are also desirable because quantifying multiple 
sources of bias may become unmanageable and may create significant challenges to making 
inference from electronic data(19). 
To address misclassification using traditional quantitative bias approaches, two bias 
parameters for the misclassified variable are needed:  sensitivity and specificity.  In a simple 
bias analysis, these bias parameters, along with the observed risk ratio, can be used to 
calculate the risk ratio that would have been observed had the misclassification not existed or 
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had the covariate been measured in the study(19).  Probabilistic bias analysis (PBA) is an 
extension of QBA that acknowledges that exact bias parameters are not necessarily known. 
In PBA, a range of bias parameters is established, parameters are sampled multiple times (for 
example, 1,000 times), and QBA is conducted that many times.  Then, a measure of central 
tendency and range for all bias-corrected estimates is reported(19). 
 A methodological challenge for QBA is that the bias parameters needed to correct for 
misclassification are not always known.  A complementary approach is to posit scenarios for 
these bias parameters and show situations where inference would be changed if adjustment 
for the covariate had occurred.  This is then followed with a qualitative evaluation of whether 
those situations are plausible(19, 97).   
While textbooks and tutorials on quantitative bias analyses are available, these 
approaches do not currently have widespread use in epidemiological research(20).  There has 
been very limited use of these approaches in EHR-based research(21).  As discussed earlier, 
developing and validating algorithms for outcome identification has become an important 
component of EHR-based research.  However, there is currently limited methodological 
work in using the information collected from such validation studies to then quantify the bias 
caused by misclassification.  Moreover, PPVs are the most commonly used metric of 
algorithm validity in electronic database research(13), so application of QBA using 
predictive values merits investigation for EHR-based research.  Finally, there is a need for 
guidance for VSD and other research on how to apply the various QBA techniques available 






 Most vaccine safety research in the U.S. has focused on individual vaccines and acute 
adverse events, and many post-marketing surveillance studies are conducted with EHR data.  
Outcome misclassification in EHR data has been a methodological challenge in these studies, 
and researchers typically counter this problem by adjudicating all observed outcomes through 
a medical chart review.  However, new initiatives by the CDC’s Vaccine Safety Datalink 
include studies of immunization schedule safety, where risks of chronic outcomes are 
compared between children who do and do not get vaccinated per the U.S. recommended 
immunization schedule.  In these studies, chart reviews of all the hundreds or thousands of 
observed outcomes may not be feasible.  Furthermore, outcome false negatives are also a 
methodological concern. 
 Outcome validation studies are routinely conducted in EHR-based research, and 
qualitative evaluations as to the potential for bias based on the overall values of 
misclassification metrics (sensitivity, specificity, PPV and NPV) are common.   However, 
epidemiologists have long warned that the bias caused by misclassification cannot be 
predicted simply by misclassification metrics alone, and that even small amounts of 
misclassification can cause large bias(72).  Immunization schedule safety studies may have 
direct implications for U.S. immunization policy; therefore, it is important to addressing bias 
from misclassification of outcomes.    
Infrequently-used methods from the field of quantitative bias analysis show promise 
for this line of research, but additional work is needed to convince researchers as to the 
importance of quantifying misclassification bias, and to also showcase the QBA methods that 
may be most accessible for electronic database research.  The results from this dissertation 
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assess the effectiveness of both traditional QBA approaches using outcome sensitivity and 
specificity estimates (Aim 1b) and of less-traditional predictive value-based QBA approaches 
(Aim 2).  The effectiveness of these methods will be compared to qualitatively evaluating the 
potential for bias based on overall misclassification metrics (Aim 1a).   Finally, researchers 
with be provided with practical guidance for implementing quantitative bias analysis in 














































Diseased True Positives (TP) False Positives (FP) 










































Sensitivity (SN)  TP / (TP + FN) 
Specificity (SP) TN / (TN + FP) 
Positive Predictive Value (PPV) TP / (TP + FP) 
Negative Predictive Value (NPV)  TN / (FN+TN) 




























Table 3:  Reasons for and examples of outcome misclassification in vaccine research 
using electronic databases  
Reason 
 
Published example(s) from vaccine safety research 
Miscoding 
Incorrect electronic code 
applied to medical record 
 




Electronic code applied to 
medical record during clinical 




 In a study of meningococcal conjugate vaccine safety, a rule-out of a 
differential diagnosis of Guillain-Barre syndrome (GBS) was identified 
through chart review(89) 
 After reviewing charts of cardiac events following influenza vaccine, 1 of 8 
identified diagnoses was a rule-out of cardiomegaly(92) 
 In a study of adverse events following DTaP-IPV vaccine, GBS was ruled 
out in a child presenting to a hospital two days post-vaccination with lower 
and upper extremity weakness(98) 
Prevalent conditions 
Code for an acute clinical 
condition is used for a 
prevalent condition 
 
 Guillain-Barre syndrome diagnosis codes identified after vaccination 
representing prevalent disease(89) 
Misdiagnosis 




 Use of ataxia code for disparate gait issues identified in a study of measles-
mumps-rubella-varicella vaccine safety(89) 
Outside use of services 
Patient accesses medical care 
that is not captured in the 
electronic database 
 
 Use of alternative medical providers, such as chiropractors, was positively 




Individuals have varying 
propensity to seek medical 
care, especially for non-urgent 
conditions 
 A higher rate of post-vaccination adverse events in emergency department 
settings was identified among children who are first in birth order versus 
later birth order. This finding is likely due to parents’ inexperience and 
anxiety regarding common, non-serious vaccine adverse events, such as 
fever and irritability(99).  




 In an electronic signal identified for hypotension following pediatric 
influenza vaccine, 2 of 7 hypotension diagnoses were due to children 
accidentally ingesting antihypertensive medication(92) 
 Following medical record review of anaphylaxis on the day of vaccination, 
only 7% were confirmed to be incident anaphylactic events(91).  In some 
cases, anaphylaxis was coded in conjunctions with prescription for an 




Table 4:   Framework for developing and evaluating outcomes in electronic health 






 Consider how the likelihood of seeking care is influenced by an 
illness’ acuity and severity  
  
 Determine the diagnoses codes, procedures, diagnostic tests and 





 Ascertain whether clinical data for patients in the database are 
complete, and whether there are time periods or clinical settings 
where EHR data may be incomplete 
  






 Identify published EHR-based outcome identification algorithms, 
and determine whether such algorithms would perform similarly in 
your population, time period, and database 
  
 Assess whether conducting an outcome validation is feasible 
  
 Measure the impact of outcome misclassification through 












Table 5:  Published estimates of sensitivity, specificity, positive predictive values, or 
negative predictive values for outcomes prioritized for immunization schedule safety 
research1 
 
Outcome Study description and 
setting (reference 
number) 
General description of algorithm Misclassification 






Anaphylaxis Manual review of 
provider notes for 
anaphylaxis diagnoses 
on the day of 
vaccination at nine 
managed care 
organizations in the 
Vaccine Safety 
Datalink(91)  
Specific diagnosis code for 
anaphylactic shock on days 0 to 2 
after vaccination,  
or external cause of injury code for 
any adverse reaction to vaccines on 
day 0, without same code within 2 
days prior to vaccination, 
or non-specific allergic reaction code 
on day 0, without a previous code in 
42 days 
 
Of 1,117 cases 
reviewed, 76 met case 






Anaphylaxis Validation of a sample 
of records with 
diagnosis codes for 
anaphylaxis from five 
Food and Drug 
Administration Mini-
Sentinel Partners(100) 
1 inpatient or emergency department 
encounter with a specific diagnosis 
code for anaphylactic shock,  
or 1 outpatient encounter with a 
specific diagnosis code for 
anaphylactic shock, plus a code for 
an associated symptom, procedure, or 
treatment,  
or a diagnosis code for a non-specific 
allergic reaction in an inpatient or 
emergency department setting, plus 
two additional codes for symptoms, 
procedures, or treatments associated 
with anaphylaxis 
 
PPV = 63.1% (53.9% - 
71.7%) 
Asthma Validation of the 
Council of State and 
Territorial 
Epidemiologists 
definition of “probable” 
asthma within a 
Medicaid pediatric 
population and a 
managed care pediatric 
population(14) 
For “probable” asthma: ≥ 1 
emergency department or inpatient 
visit for asthma,  
or ≥ 3 outpatient visits with a ICD-9 
diagnosis code for asthma, or ≥ 1 
dispensing for an anti-inflammatory 
drug 
SN = 84% (81% – 
86%) 
SP = 93% (92% – 94%) 
PPV = 79% (76% – 
81%) 





Table 5 continued: 
 
Outcome Study description and 
setting (reference 
number) 
General description of 
algorithm* 
Misclassification 






Asthma Validation through 
survey of patients with 
and without asthma 
identified from primary 
care clinics in Ontario, 
Canada(101) 
≥ 2 diagnosis codes for 
asthma in the outpatient 
setting within 2 years or ≥ 1 
diagnosis code in an inpatient 
setting  
SN = 83.8% (77.1% - 
89.1%) 
SP = 76.5% (71.8% - 
80.8%) 
PPV = 61.5% (54.7% - 
68.0%) 






Manual review of a 
sample of charts for 
children ages 3 to 9 years 
meeting the algorithm 
criteria for ADHD, 
identified from electronic 
health record data from 
10 managed care 
organizations(102) 
≥ 2 encounters in primary 
care, pediatric, or mental 
health outpatient clinics with 
a diagnosis code for ADHD 
between 7 and 365 days apart 
Confirmation rate** for 
children ages 3-5 years:  
71.5% (56.5% - 86.4%) 
 
For children ages 6-9 
years: 
73.6% (65.6% - 81.6%) 
 




urticaria at four asthma 
and allergy centers in the 
U.S.(16) 
  
≥ 2 ICD-9 urticaria codes in 
an outpatient setting, 
or 1 ICD-9 urticaria code 
plus an ICD-9 code for 
angioedema 
 
SN = 71.1% 
PPV = 90.4% 
Diabetes Validation of various 
algorithms for 
identifying pediatric 
diabetes using electronic 
health record data from a 




≥ 1 outpatient visit with an 
ICD-9 diagnosis code for 
diabetes, 
or a prescription for insulin  
SN = 95.9% (94.8% - 
96.8%) 
PPV = 95.5% (94.4% - 
96.4%) 
SP ≥ 99.8%  
NPV ≥ 99.8% 
Study reported that SP 
and NPV were between 






Table 5 continued: 
 
Outcome Study description and 
setting (reference 
number) 
General description of 
algorithm* 
Misclassification 






Encephalopathy Validation of identifying 
central nervous system 
syndromes using 
electronic health record 
data from an emergency 
department setting at 
University Health Care 
in Salt Lake City, Utah, 
U.S.(103) 
Abnormal cerebrospinal fluid 
>5 white blood cells per high 
power field, plus a diagnosis 
code for either meningitis or 
encephalitis by lab order 
SN = 91% 
SP = 99% 
PPV = 12% 




Validation of diagnosis 
codes identified in 
electronic health record 
data at Kaiser 
Permanente Northern 
California(104) 
Diagnosis code for 
rheumatoid arthritis in 
inpatient or outpatient setting 
Proportion confirmed: 
47.1% 
Seizures Validation of febrile 
seizures identified in 
electronic health record 
data from seven managed 
care organizations in the 
Vaccine Safety 
Datalink(90) 
Diagnosis code for seizure in 
any setting, 0-30 days 
following a pneumococcal 
vaccination 
PPV = 96.6% (93.1% - 
98.6%) 
1. Abbreviations: SN = sensitivity, SP = specificity, PPV = positive predictive value, NPV = negative predictive 
value.  
2. The terms “confirmation rate” and “proportion confirmed” have previously been used to represent the 
percentage of confirmed outcomes out of a sample of those identified through the outcome-identifying 














































Low systematic error 
High random error 
Example: 
Observed RR=2.00 
Observed 95% CI=  
0.95 – 3.05 
 
1b: 
High systematic error 
Low random error 
Example: 
Observed RR=1.00 
Observed 95% CI=  
0.95 – 1.05 
 
1c: 
Low systematic error 
Low random error 
Example: 
Observed RR=2.00 
Observed 95% CI=  





BIAS FROM OUTCOME MISCLASSIFICATION IN IMMUNIZATION SCHEDULE 
SAFETY RESEARCH1 
3.1 Introduction 
Large, linked databases, such as the Centers for Disease Control and Prevention’s 
Vaccine Safety Datalink (VSD) and the Food and Drug Administration’s Post-Licensure 
Rapid Immunization Safety Monitoring Program (PRISM), are important resources for post-
market studies of vaccine safety(28-30). These systems capture data on millions of 
individuals and billions of medical encounters from electronic health records (EHR) and 
medical billing claims(29, 105).  Clinical outcomes are identified with electronic data 
algorithms, which are typically individual or combinations of diagnosis codes(12, 106). 
In studies of acute vaccine adverse events, presumptive outcomes are identified in 
electronic data within short risk and control periods around vaccination. Misclassification of 
these presumptive outcomes has been a key challenge in this research(29). Common reasons 
for misclassification include clinician miscoding and rule-out diagnoses(106).  To avoid 
misclassification bias, researchers often chart review all presumed outcomes, and then re-
analyze data with only confirmed outcomes(29).  The percent of presumed outcomes 
confirmed is typically reported as a positive predictive value (PPV) or confirmation 
                                                           
1 Portions of this chapter were previously published in Pharmacoepidemiology and Drug Safety and are 
included with the permission of the copyright holder. The reference for the published work is:  Newcomer SR, 
Kulldorff M, Xu S, Daley MF, Fireman B, Lewis E, Glanz J. Bias from outcome misclassification in 
immunization schedule safety research. Pharmacoepidemiology and Drug Safety. Sophia Newcomer is the 




rate(107). Vaccine safety studies have demonstrated considerable variability in outcome 
PPVs, ranging from 5% to 97%(90, 91).  
While there has been ample research on acute outcomes following vaccination, a 
2013 Institute of Medicine (IOM) report called for studies of chronic outcomes, such as 
autoimmune and allergic diseases, following cumulative exposure to early childhood 
immunizations(7). The VSD has embarked on such studies of immunization schedule 
studies(8), but this research poses new challenges for addressing outcome misclassification 
bias. Unlike studies of acute outcomes, observation time will span years. It may not be 
feasible to adjudicate the hundreds or thousands of presumptive outcomes identified in 
electronic data(8).  Furthermore, outcome sensitivity is a concern, since for some non-acute 
conditions, parents may have varying propensity to seek care for their children, or may 
consult external providers not captured in electronic health records(87).   
In this study, we used simulations to evaluate one method for assessing and another 
method for correcting bias of an immunization schedule-outcome association due to outcome 
misclassification in EHR data.  The first method involves using overall outcome PPVs to 
assess misclassification bias.  PPVs are the most commonly reported measure of electronic 
algorithm validity in EHR-based research(13). For immunization schedule safety studies, 
researchers could validate a sample of presumptive outcomes and estimate an outcome PPV.  
While it has been suggested that PPV levels >70% are sufficient for electronic-only data 
analysis(11), the relation between overall outcome PPVs and bias of an exposure-outcome 
association has not been investigated for EHR-based vaccine schedule safety research.  We 
also evaluated quantitative bias analyses (QBA), which are methods for correcting systematic 
error in epidemiological research(19, 20). Traditional QBA formulas for outcome 
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misclassification apply sensitivity and specificity estimates to a study’s observed relative 
risk.  Previous studies have reported the sensitivity and specificity for several chronic 
outcomes of interest in immunization schedule safety studies(14-18); these measures could 
be used as bias parameters in QBA.   
  For our primary objective, we evaluated whether outcome PPVs are effective 
indicators of bias of an immunization schedule-outcome association.  To achieve this 
objective, we constructed simulations modeled on VSD studies that have been proposed or 
are ongoing, applied outcome misclassification levels previously measured in EHR data, and 
calculated the resulting misclassification bias and outcome PPVs.  As a secondary objective, 
we tested the effectiveness of QBA for outcome misclassification within the same 
simulations(19, 20). We examined both outcome misclassification that is independent of 
exposure (non-differential misclassification), and misclassification that systematically varies 
by exposure (differential misclassification). 
3.2 Methods 
3.2.a. Study setting 
We sought to have our simulations mimic actual VSD cohort studies of immunization 
schedule safety. To achieve this goal, we first identified a cohort of children born 2002-2012 
from two managed care organizations (MCOs) participating in the VSD, Kaiser Permanente 
Colorado and Kaiser Permanente Northern California.  We further limited the cohort to 
children continuously enrolled in their MCO from birth to their 2nd birthday, which is the 
period when early childhood immunizations are administered(108). We used actual 
birthdates and MCO enrollment time (i.e., person-time) in our analyses; all other data in this 
study were simulated.   
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Both MCOs’ Institutional Review Boards approved this study; informed consent was 
not required.   
3.2.b. Simulations  
 Within this VSD cohort, we constructed simulations of immunization schedule safety 
studies, where risks of chronic outcomes are compared between groups of children with 
different immunization patterns in early childhood (ages 0-2 years). Table 6 provides an 
overview of our simulations, relative risk (RR) levels, and outcome misclassification 
scenarios. We simulated outcomes with the formula(37, 109, 110):  




     (1) 
,where p(outcome=1) is an individual’s probability of having the outcome, pt is person-time 
contributed (in days) from each child’s 2nd birthday to the first of MCO disenrollment or 8th 
birthday, β0 is the log of baseline outcome rate (per day), β1 is the log of the simulated RR, 
and X1 indicates under-vaccination exposure.  The second term in equation (1) represents the 
daily probability of experiencing an outcome. The probability of experiencing an outcome 
during the entire follow-up period is the product of the daily probability and pt. Simulated 
RR refers to the true RR representing the association between under-vaccination exposure 
and outcome, absent of any bias.  
The 2013 IOM report requested studies comparing risk of chronic outcomes in 
children who receive no vaccines or are vaccinated per distinct alternative immunization 
schedules versus children fully-vaccinated per the U.S. Advisory Committee on 
Immunization Practices’ (ACIP) recommended schedule(7, 108). Therefore, for X1, we 
focused on children with no vaccines before their 2nd birthday and children whose parents 
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choose distinct alternative schedules popularized in books or on the internet(4, 64, 68).  
Based on previous research, we simulated the prevalence of these two groups at 0.7% and 
2.4%, respectively.  The unexposed group was children fully-vaccinated per the ACIP 
schedule with a prevalence of 60.6%(67).  The remaining 36.3% of children are assumed to 
be missing some vaccine doses or are under-vaccinated at some point but get caught up 
before their 2nd birthday; these less distinct patterns of under-vaccination were not considered 
in this study.  
We simulated two levels of baseline outcome incidence: 100 and 1000 outcomes per 
100,000 person-years. We chose these rates to represent both rare (e.g., Type 1 diabetes, 
epilepsy) and more common (e.g., allergic conditions, asthma) conditions from a priority list 
of outcomes for VSD immunization schedule research(8).  Within each of four simulations 
(one for each of 2 exposure groups and 2 baseline outcome incidence levels), we separately 
simulated three levels of RR:  2.00, 1.00, and 0.50. For each simulation and RR level, we 
created 1,000 replicated datasets with a different random seed.  Within each replication, 
exposure probabilities were applied to each child, and Bernoulli trials determined which 
children were assigned exposure to an under-vaccination pattern. Formula 1 was used to 
assign probability of outcome, and Bernoulli trials determined the outcome status for each 
child.   
3.2.c. Misclassification  
 We reviewed published studies to identify ranges of likely outcome misclassification 
levels in VSD immunization schedule research.  We identified validation studies of EHR-
based algorithms for two outcomes of interest: asthma and Type 1 diabetes(8).  The best 
performing algorithms had sensitivity>95% and specificity>99%(14, 15).  For each 
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simulation and RR, we made four copies of the 1,000 replicated datasets and tested two 
scenarios of non-differential and two scenarios of differential outcome misclassification 
based on these levels (Table 6, scenarios A-D).  For one differential outcome 
misclassification scenario, we measured bias with lower outcome sensitivity among under-
vaccinated children. Some parents who refuse vaccines express distrust in traditional 
medicine and may seek care outside the MCO(87), leading to decreased outcome sensitivity. 
We then measured bias from lower outcome specificity among under-vaccinated children. 
Clinicians may be more likely to suspect infectious conditions in ill children who are under-
vaccinated, which could lead to more “rule-out” diagnoses and higher false positive rates.  
 When testing the two non-differential outcome misclassification scenarios, we 
applied sensitivity and specificity levels from Table 6 to the simulated datasets without 
regard to exposure.  For the two presentations of differential misclassification, sensitivity and 
specificity were applied separately by exposure. Bernoulli trials determined which children 
“flipped” to an outcome false positive or false negative status, representing EHR data 
misclassification.   
3.2.d. Analysis 
We calculated the observed RR, using Poisson regression with a log of person-time as 
the offset, within each replication.  The observed RR is the immunization schedule exposure-
outcome association estimated with outcome misclassification present. For each simulated 
immunization schedule safety study, simulated RR level, and misclassification scenario, we 
reported bias as the median observed RR with misclassification across replications.  
For each simulation and RR level, we reported the median PPVs that resulted from 
each outcome misclassification scenario.  When simulated RR≠1.00, we reported empirical 
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power with and without outcome misclassification.  We calculated empirical power as the 
percent of replications where the null hypothesis was rejected at alpha=0.05 in the same 
direction as the simulated RR.  We calculated Type 1 error for simulations with simulated 
RR=1.00 as the percent of replications with null hypothesis rejection at alpha=0.05.   
 We tested the effectiveness of QBA using formulas for both QBA assuming non-
differential outcome misclassification and assuming differential outcome misclassification 
(see Appendix D for QBA formulas)(19). To conduct the QBA, we determined the number of 
observed individuals that were exposed with outcome, exposed without outcome, unexposed 
with outcome, and unexposed without outcome in each simulated replication. We then 
applied QBA formulas with sensitivity and specificity measured from each replication and 
calculated the RR that would have been observed had misclassification not been present.  We 
reported the median QBA-corrected RRs across replications.  
All simulations and analyses were conducted using SAS 9.4®.  
3.3 Results  
Across replications there were an average of n=1,722 children simulated to be 
completely unvaccinated (simulations #1 and #2), n=6,117 children simulated to be on a 
distinct alternative schedule (simulations #3 and #4), and n=155,722 children simulated to be 
adhering to the ACIP schedule (unexposed group in all simulations).  We observed a range of 
bias across the simulations, levels of simulated (i.e., true) RR, and misclassification scenarios 
tested. Across simulations, overall median outcome PPVs ranged from 34%-98%.  With non-
differential misclassification, median bias was across replications was towards the null and 
overall outcome PPVs were associated with the magnitude of median bias (Tables 7 and 8, 
scenarios A and B). For example, when true RR=2.00, the median observed RR was 1.33 
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when the median PPV=34%, and the median observed RR was 1.83 when the median 
PPV=85%. When the median PPV was 98%, there was virtually no bias of the median RR.   
When outcome misclassification was differential to exposure, the direction of median 
bias varied and overall PPVs were not indicators of the direction or magnitude of median 
bias (Tables 7 and 8, scenarios C and D).  For example, when true RR=2.00 and the baseline 
outcome rate was 1,000/100,000 person-years, the median observed RR was 1.65 when 
outcome sensitivity was lower among under-vaccinated children and 2.23 when specificity 
was lower among under-vaccinated children. In both scenarios, median overall outcome 
PPVs were 91% or 92%.  In some simulations, differential misclassification caused extreme 
median bias.  For example, in simulation #1, with lower specificity among under-vaccinated 
children (scenario D), the observed median RR was 2.72 when true RR=0.50, and median 
PPV=50%.  
3.3.a. Power and type 1 error 
In some simulations, outcome misclassification led to reductions in power (Table 9).  
For example, for true RR=2.00 in simulation #1, power was reduced from 78% without any 
misclassification to 70% with non-differential specificity=99.9% and PPV=84% (scenario 
B), and further down to 40% power with non-differential specificity=99.0% and PPV=34% 
(scenario A).  Change in power varied by true RR within the same differential 
misclassification scenario.  For example, when specificity was lower among under-
vaccinated children (scenario D), the higher outcome false positive rate in this exposed group 
led to consistent overestimation of the true effect.  Therefore, when simulated RR=0.50, 
power was reduced from 100% without misclassification to 17% with misclassification, but 
power remained at 100% when RR=2.00.  
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Before misclassification was applied, Type 1 error was near 5% in all simulations 
where simulated RR=1.00. Non-differential outcome misclassification did not affect these 
rates (results not shown).  However, differential misclassification led to Type 1 error up to 
100%, and overall PPV levels were not associated with these rates (Table 10).  For example, 
in simulations #3 and #4 with differential outcome sensitivity (scenario C), median 
PPV=51% and Type 1 error=7.1% when the baseline outcome rate was 100/100,000 person-
years. In contrast, median PPV=92% and Type 1 error=67.8% when the baseline outcome 
rate was 1,000/100,000 person-years. While the higher false negative rate among under-
vaccinated children led to bias toward observing a protective effect, the specificity of 99.5% 
more rapidly caused the observed effect back toward the null with the rarer outcome, leading 
to lower Type 1 error.  
3.3.b. Quantitative bias analysis 
 In most simulations of non-differential misclassification, QBA assuming non-
differential misclassification corrected bias (Tables 7, 8 and 10).  When true RR=2.00, QBA 
assuming non-differential misclassification resulted in perfect or near-perfect bias correction.  
QBA assuming non-differential misclassification was also effective when true RR=0.50, 
except in Simulation #1.  In that simulation with completely unvaccinated children and the 
rarer outcome, median bias-corrected RR was 0.67 with QBA assuming non-differential 
misclassification.  This median bias-corrected RR was closer to the true value of RR=0.50 
than the median RR observed with misclassification of 0.84.  
 QBA using outcome sensitivity and specificity measurements by exposure group led 
to nearly perfect correction of bias in all simulations.  Unsurprisingly, when misclassification 
was simulated to be differential by exposure, QBA assuming non-differential 
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misclassification was ineffective, and sometimes resulted in estimates that were more biased 
than the estimates observed under misclassification. 
3.4 Discussion 
 While numerous studies have reported on misclassification in 
pharmacoepidemiologic databases(9-13), there has been limited work in quantifying the bias 
that arises from such misclassification and on methods for correcting this bias. To our 
knowledge, there has been no prior work on evaluating and correcting misclassification bias 
in vaccine schedule research studies. Using simulations, we quantified a range of bias across 
plausible scenarios of non-differential and differential outcome misclassification. Our results 
suggest that rather than relying on overall PPVs as indicators of bias, quantitative methods 
should be used to account for misclassification bias. 
Our results highlight several reasons why overall outcome PPVs may not be effective 
indicators of bias of an exposure-outcome association.  First, while median PPVs were 
associated with the magnitude of median bias with non-differential misclassification, they 
were not associated with the magnitude or direction of median bias with differential 
misclassification. In immunization schedule research, differential outcome misclassification 
could occur due to parent or provider behavior(5, 8, 87). Even if non-differential outcome 
misclassification is presumed, exactly equal misclassification levels across exposure groups 
is not guaranteed(74). Differential misclassification can lead to bias toward or away from the 
null, and the direction of bias is often unpredictable(73, 86). Second, since predictive values 
are a function of three factors (specificity, sensitivity, and prevalence; see Appendix C for 
Bayes’ rule relating these factors)(106, 111), PPVs can fluctuate based on any of these 
factors. For example, we observed extreme differences in PPV, from 34% to 84%, from a 
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0.9% difference in specificity when outcome prevalence was low.  Since overall outcome 
PPVs do not reflect the distribution of false positives by exposure (an underlying cause of 
bias of an exposure-outcome association), these metrics have limited utility for assessing bias 
in individual studies.  Instead, quantitative methods to adjust for systematic error should be 
considered.  
While QBA has been advocated as an essential tool in epidemiological research(20, 
72), these methods have had limited use in vaccine safety and EHR-based research(12, 21, 
78). The tendency to underestimate misclassification error, along with a lack of practical 
examples, have been identified as barriers to implementing QBA(20). We addressed these 
barriers by measuring bias via simulation, and by evaluating the application of QBA in 
immunization schedule safety research.  Our results showed that QBA was typically effective 
in correcting outcome misclassification bias.  However, similar to previous findings by 
Johnson and colleagues, we found that QBA is vulnerable to assumptions made and bias 
parameters used(79).  For example, in simulation #1, with a rare exposure and rare outcome, 
QBA assuming non-differential misclassification did not effectively correct misclassification 
bias when true RR=0.50, even though the underlying misclassification process was non-
differential. This was due to differences in sensitivity and specificity by exposure that 
occurred due to chance.   
For traditional QBA methods to be most effective in immunization schedule research, 
our results suggest that outcome sensitivity and specificity should be estimated by exposure.  
Since collecting such data may not be feasible, an alternative approach is to establish ranges 
of plausible sensitivity and specificity levels by exposure, and use probabilistic bias analysis 
to quantify a range of corrected RRs(19, 21). Less-established quantitative bias approaches 
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using predictive values are available(19, 76, 112). However, these methods come with 
challenges, including requiring positive and negative predictive values stratified by 
exposure(19), or assuming non-differential outcome sensitivity(76). While we investigated 
traditional QBA methods for misclassification using sensitivity and specificity measures, 
evaluation of predictive value-based approaches is also warranted in EHR-based research.  
Our study has several limitations.  Our simulations did not incorporate all outcome 
misclassification levels encountered in immunization schedule safety research.  Also, while 
our differential misclassification scenarios were based on practical concerns in immunization 
schedule research, it is unknown how different outcome sensitivity and specificity levels are 
across exposure groups, since these data have not been collected. As a result, our simulations 
may have over- or under-estimated the misclassification bias that may be encountered in this 
line of research. Moreover, our simulations only focused on bias from misclassification of 
binary outcomes. Exposure misclassification due to missing vaccine records is also a 
concern. Addressing measurement error of exposures, covariates, and of continuous or multi-
level outcome variables, along with bias from unmeasured confounding, involves more 
complex bias analyses which merit further evaluation within EHR-based research(19). 
Finally, we only considered bias of risk ratios, and did not evaluate how outcome 
misclassification in EHR data would affect measures of risk difference.   
Research using electronic databases are essential to U.S. vaccine safety, and 
improved methods for quantifying and communicating about uncertainty in this line of 
research are needed(113).  While our simulations were conducted in the context of 
immunization schedule safety research, our findings are broadly applicable to other EHR-
based pharmacoepidemiological research. Our results serve to encourage researchers to 
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acknowledge the potential for misclassification bias in EHR-based studies, and to use 



































Table 6:   Description of simulations, levels of relative risk, and outcome 
misclassification1 
 
Simulated immunization schedule safety study2 Levels of simulated 
relative risk (RR)  
Outcome misclassification scenarios 
 
Sensitivity (SN) and specificity (SP) levels  
applied to each simulation  







































B: Non-differential outcome 




C: Differential outcome misclassification, 





D:  Differential outcome misclassification, 


























1. Abbreviations: RR=relative risk; SN=overall sensitivity; SP=overall specificity; SN1=sensitivity among exposed; 
SN0=sensitivity among unexposed; SP1=specificity among exposed; SP0=specificity among unexposed. 
2. 1,000 replicated datasets were generated for each simulation and relative risk level using probabilistic modeling.  Four 
copies of these 1,000 datasets were generated to test the two non-differential and two differential outcome misclassification 
processes. 
3. We simulated the prevalence of completely unvaccinated children to be 0.7% and children on distinct alternative 
immunization schedules to be 2.4%. We simulated the unexposed group to be children fully-vaccinated per the U.S. 
Advisory Committee on Immunization Practices’ recommended schedule, with an estimated prevalence of 60.6%.  The 
remaining 36.3% of children are assumed to be missing some vaccine doses or are under-vaccinated at some point but get 
caught up on vaccines before their 2nd birthday, and these under-vaccination patterns were not considered in this study.  
4. The lower sensitivity (scenario C) and specificity (scenario D) levels occur in a rare exposure group.  Since overall 
outcome sensitivity and specificity levels will be a weighted average of these levels from across the exposed and 
unexposed groups, the overall observed sensitivity and specificity will be closer to the value in the more 




Table 7:  Median outcome positive predictive value, observed relative risk (RR) with 





Simulation Number 1 2 3 4 
Exposure Group Unvaccinated children  Distinct alternative 
immunization schedules 
Baseline outcome rate 
per 100,000 person-years 
100 1,000 100 1,000 
Average # of baseline 
outcomes across 
replications 
821 8,206 821 8,206 





SN = 97.5% 
SP = 99.0% 
Outcome PPV 
 
34% 84% 34% 84% 
Observed RR 
 














SN = 97.5% 




84% 98% 84% 98% 
Observed RR 
 




















51% 92% 51% 92% 
Observed RR 
 
















Simulation Number 1 2 3 4 
Exposure Group Unvaccinated children  Distinct alternative 
immunization 
schedules 
Baseline outcome rate 
per 100,000 person-years 
100 1,000 100 1,000 
Average # of baseline 
outcomes across 
replications 
821 8,206 821 8,206 












50% 92% 47% 90% 
Observed RR 
 








0.48 0.50 0.50 0.50 
1. Abbreviations:  SN=overall sensitivity; SP=overall specificity; SN1=sensitivity among exposed; 
SN0=sensitivity among unexposed; SP1=specificity among exposed; SP0=specificity among unexposed; 


















Table 8:  Median outcome positive predictive value, observed relative risk (RR) with 








Simulation Number 1 2 3 4 






Baseline outcome rate per 
100,000 person-years 
100 1,000 100 1,000 
Average # of baseline outcomes 
across replications 
821 8,206 821 8,206 






SN = 97.5% 
SP = 99.0% 
Outcome PPV 
 
34% 85% 35% 85% 
Observed RR 
 
1.33 1.83 1.34 1.84 
QBA-corrected RR, assuming non-
differential misclassification 
1.99 2.00 2.00 2.00 
QBA-corrected RR, assuming 
differential misclassification 





SN = 97.5% 
SP = 99.9% 
Outcome PPV 
 
84% 98% 84% 98% 
Observed RR 
 
1.83 1.98 1.83 1.98 
QBA-corrected RR, assuming non-
differential misclassification 
1.99 2.00 2.00 2.00 
QBA-corrected RR, assuming 
differential misclassification 












51% 92% 52% 92% 
Observed RR 
 
1.35 1.65 1.37 1.65 
QBA-corrected RR, assuming non-
differential misclassification 
1.68 1.72 1.73 1.72 
QBA-corrected RR, assuming 
differential misclassification 











Simulation Number 1 2 3 4 






Baseline outcome rate per 
100,000 person-years 
100 1,000 100 1,000 
Average # of baseline outcomes 
across replications 
821 8,206 821 8,206 












50% 91% 48% 91% 
Observed RR 
 
3.46 2.23 3.46 2.23 
QBA-corrected RR, assuming non-
differential misclassification 
6.10 2.36 6.71 2.37 
QBA-corrected RR, assuming 
differential misclassification 
2.00 2.00 2.00 2.00 
1. Abbreviations:  SN=overall sensitivity; SP=overall specificity; SN1=sensitivity among exposed; 
SN0=sensitivity among unexposed; SP1=specificity among exposed; SP0=specificity among unexposed; 






















Table 9: Empirical power with and without outcome misclassification1 
 
Simulation Number 1 2 3 4 
Exposure Group Unvaccinated children  Distinct alternative 
immunization 
schedules 
Baseline outcome rate per 100,000 person-
years 
100 1,000 100 1,000 
     
Simulated RR=0.50     
Power without misclassification 22% 100% 85% 100% 
Power with misclassification:     
A: Non-differential misclassification 
SN = 97.5%, SP = 99.0% 
 
9% 100% 35% 100% 
B: Non-differential misclassification 
SN = 97.5%, SP = 99.9% 
 
19% 100% 75% 100% 




17% 100% 65% 100% 




0% 17% 0% 52% 
Simulated RR=2.00     
Power without misclassification 78% 100% 100% 100% 
Power with misclassification:     
A: Non-differential misclassification 
SN = 97.5%, SP = 99.0% 
 
40% 100% 86% 100% 
B: Non-differential misclassification 
SN = 97.5%, SP = 99.9% 
 
70% 100% 99% 100% 









Table 9 continued: 
 
Simulation Number 1 2 3 4 
Exposure Group Unvaccinated children  Distinct alternative 
immunization 
schedules 
Baseline outcome rate per 100,000 person-
years 
100 1,000 100 1,000 




100% 100% 100% 100% 
1. Empirical power was calculated as the percent of simulated replications where the null hypothesis was 
rejected at alpha=0.05 in the same direction as the simulated RR (i.e., the observed RR is >1.0 for simulated 




























Table 10:  Median outcome positive predictive value, observed relative risk (RR) with 
misclassification, Type 1 error rate, and bias-corrected RRs with quantitative bias 







Simulation Number 1 2 3 4 
Exposure Group Unvaccinated children  Distinct alternative 
immunization schedules 
Baseline outcome 
rate per 100,000 
person-years 
100 1,000 100 1,000 
Type 1 error rate 
without 
misclassification 












51% 92% 51% 92% 
Observed RR 
 
0.91 0.87 0.92 0.87 
Type 1 error rate with 
misclassification 





















50% 91% 47% 90% 
Observed RR 
 
2.94 1.34 2.97 1.34 
Type 1 error rate with 
misclassification 









1.00 1.00 1.00 1.00 
1. Abbreviations:  SN=overall sensitivity; SP=overall specificity; SN1=sensitivity among exposed; 
SN0=sensitivity among unexposed; SP1=specificity among exposed; SP0=specificity among unexposed; 






PUTTING OUTCOME VALIDATION STUDY RESULTS TO GOOD USE:  
QUANTITATIVE BIAS ANALYSIS USING POSITIVE PREDICTIVE VALUES 
4.1        Introduction  
“Big data” sources such as electronic health record (EHR) and claims databases are 
increasingly relied on for epidemiologic research(81, 82, 114).  However, misclassification 
of clinical outcomes is a major threat to validity in these studies(78, 114). Outcome 
misclassification occurs when an individual’s disease status is incorrectly identified in 
electronic data.  For example, outcome false positives occur when the diagnostic or 
procedural codes used do not reflect the true medical issue or when a clinician applies a code 
to a patient’s medical record but later rules out the condition(106). Outcome false negatives 
occur when patients do not seek medical treatment for clinical conditions, or seek care 
outside of the medical institutions contributing to the electronic data-based study(106). 
Applying an incorrect code to a patient’s record (i.e. miscoding) can lead to both false 
positives and false negatives.   
Outcome validation has been encouraged in electronic data-based research, with 
numerous studies reporting the sensitivity, specificity, positive predictive value (PPV) or 
negative predictive value (NPV) of algorithms for identifying clinical outcomes in these data 
sources(9, 12, 13, 83, 106).  PPVs are the most accessible validity measures to researchers 
using electronic databases, since estimation relies on adjudicating a sample of presumptive 
outcomes(13). In contrast, estimating sensitivity and specificity is contingent on having true 
diseased or non-diseased cohorts with which to compare an outcome-identifying algorithm in 
electronic health data.  For decades, epidemiologists have warned that even small amounts of 
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misclassification can cause substantial bias of an exposure-outcome association(72, 74, 115). 
However, while most validation studies indicate that misclassification does exist (e.g., 
PPV<100%), there have been relatively few efforts to use the results from these studies to 
quantify, and ideally correct for, misclassification bias  
Methods for quantifying misclassification bias fall under the broad field of quantitative 
bias analysis (QBA)(20, 94). QBA provides methods for using measures of misclassification, 
called bias parameters, to quantify the magnitude and direction of bias of an exposure-disease 
association(19). These methods are ideal in studies with minimal random error, such as 
retrospective cohort studies using large EHR and claims data sources(19).  However, several 
challenges exist to implementing QBA.  A key barrier is that traditional QBA for 
misclassification relies on sensitivity and specificity estimates as bias parameters.  QBA 
methods using predictive values are available, including one method published by Lash, Fox 
and Fink that uses PPVs and NPVs stratified by exposure as bias parameters15, and one 
method published by Brenner and Gefeller that uses only PPVs stratified by exposure, under 
the assumption of non-differential sensitivity16.  Even though PPVs are the most commonly 
reported measure from validation studies(13), neither of these methods have been widely 
used in studies using EHR or claims data.  
In this paper, we review these predictive value-based QBA methods, and evaluate 
their effectiveness using simulations.  Our motivation for this work was the problem of 
misclassification bias in immunization schedule safety research(116). A 2013 Institute of 
Medicine report called for observational studies on risks of chronic outcomes in children 
whose parents choose alternative immunization schedules as compared to children whose 
parents follow the U.S. recommended immunization schedule(7). The CDC’s Vaccine Safety 
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Datalink, which coordinates a linked database from U.S. health plans for vaccine research, is 
conducting such studies(8, 29).  However, validation studies for several outcomes of interest, 
such as asthma, chronic urticaria, and diabetes(14-16), indicate that some misclassification of 
these outcomes is likely in EHR and claims data. 
The aim of this study was to test the effectiveness of two predictive value-based 
methods for correcting bias of a risk ratio due to outcome misclassification: (a) a method 
requiring both PPVs and negative predictive values (NPVs) stratified by exposure, and (b) a 
method requiring only PPVs stratified by exposure, and assuming non-differential outcome 
sensitivity, as compared to analysis of electronic data as is, ignoring misclassification bias. 
As an introduction to predictive value-based QBA approaches, we focused on retrospective 
cohort designs with binary exposures and outcomes, and on methods applied to observed, 
aggregate data.  First, we reviewed limitations of two current approaches to outcome 
misclassification in electronic database research: analyzing electronic data as is, where 
outcome misclassification bias is ignored, or using overall outcome PPVs to qualitatively 
assess the presence or magnitude of bias.  Then, we reviewed the strengths and limitations of 
two predictive value-based QBA methods(19, 76), and tested the effectiveness of these 
methods within simulations of an immunization schedule safety study. 
4.2   Limitations of current approaches to outcome misclassification  
4.2.a.  Analysis of electronic data, ignoring misclassification bias 
Often, electronic data are analyzed for pharmacoepidemiologic research as is, without 
any adjustments made for potential outcome misclassification.  Table 11 shows the observed 
cell sizes for exposure/outcome combinations (denoted as A, B, C, and D) observed in 
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electronic data. In a cohort study, the unadjusted observed RR, without considering outcome 
misclassification, is calculated using Formula 1. 
This approach assumes no misclassification of the exposure or outcome.  However, 
most validation studies indicate some outcome misclassification exists in electronic data-
based studies:  sensitivity, specificity, PPVs, or NPVs are typically less than 100%.  Even if 
such metrics are high, small amounts of misclassification can have “profound”(72) impacts 
on exposure-disease estimates(72, 115).  In fact, there are only limited situations where 
outcome misclassification will not bias an exposure-disease association.  For example, if 
outcome specificity is perfect (i.e., zero outcome false positives), and outcome sensitivity is 
non-differential to exposure, then RRs will not be biased.  However, risk difference estimates 
will be biased(86).   
4.2.b. Estimation of overall PPVs 
PPVs are the most frequently-reported measure of algorithm validity in electronic 
health data-based research(13). It has been suggested that PPVs>70% are adequate for 
analysis of electronic data(11). However, overall outcome PPVs are insufficient for 
determining the magnitude of misclassification bias.  If a PPV is less than 100%, then the 
data source is known to contain outcome false positives.  However, an overall PPV does not 
indicate how such false positives are distributed by exposure. The distribution of false 
positives, and outcome false negatives, by exposure contributes to the magnitude and 
direction of bias of an exposure-outcome association(115).   
In Appendix E, we provide examples demonstrating the limitations of relying on an 
overall PPVs for assessing the presence, magnitude or direction of outcome misclassification 
bias.  The examples mimic three hypothetical cohort studies, each with 10,000 exposed and 
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400,000 unexposed individuals, and a baseline outcome prevalence of 2.5%.  Across the 
three examples, the true RR and outcome sensitivity and specificity by exposure differs, but 
the observed RR with misclassification is the same (RRobserved =0.87), and the overall 
outcome PPV in all examples is around 93%. Despite having similar outcome PPVs and the 
same observed RR, in Example 2a there is minimal bias, in Example 2b misclassification 
bias would lead to an inaccurate conclusion as to the magnitude of the exposure effect, and in 
Example 2c bias would cause Type 1 error.  In these examples, the magnitude and direction 
of bias is affected by the differing outcome sensitivity and specificity levels by exposure, 
which can occur due to a differential misclassification process.  Also, a non-differential 
misclassification process does not guarantee that sensitivity and specificity levels will be 
exactly equal by exposure(74, 116).   
Furthermore, the focus on PPVs in electronic data-based research has distracted from 
potential bias from false negatives.  As discussed earlier, if outcome sensitivity levels are 
exactly equal across exposure groups, then no bias of a RR is caused by false negatives.  
However, differences in health care-seeking behavior could lead to differential outcome 
sensitivity in electronic data-based research(78).  For example, differences in health care-
seeking behavior have been documented in parents choose alternative immunization 
schedules for their children as compared to parents who choose to vaccinate per the U.S. 
recommended schedules(5, 87).   
4.3 Quantitative bias analysis (QBA) using predictive values 
4.3.a. Justification for outcome PPVs stratified by exposure 
Below, we introduce two published methods for applying outcome predictive values 
in QBA.  Both methods involve predictive values stratified by exposure, which is a departure 
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from current practices in electronic health data-based research, where overall outcome PPVs 
are typically reported(13).  However, predictive values are a function of sensitivity, 
specificity, and prevalence (Appendix C).  If any one of these factors differs by exposure, 
then the outcome PPV will differ by exposure. Even if sensitivity and specificity are exactly 
equal across exposure groups, outcome PPVs will still differ if a true exposure-outcome 
association exists. The PPV will be higher in the group with the higher outcome prevalence.   
4.3.b.  QBA using PPVs and NPVs stratified by exposure 
 We modified an exposure misclassification predictive value-based QBA method by 
Lash, Fox and Fink(19) for outcome misclassification (Table 12). Let PPV1 and PPV0 denote 
outcome PPVs among exposed and unexposed groups, respectively, and NPV1 and NPV0 
denote outcome NPVs among exposed and unexposed groups, respectively.  The formulas in 
Table 12 result in corrected cell sizes for each exposure/outcome combination (denoted as 
A*, B*,C*, and D*), and a corrected RR can be calculated (Formula 2) 
 A limitation of this approach in electronic health data is that NPVs cannot always be 
estimated.  To estimate a NPV, one would need to sample from individuals who did not have 
the outcome recorded in electronic data, and then determine which individuals truly did have 
the outcome.  For some outcomes, it is likely that hundreds of observed non-outcomes could 
be reviewed before any false negatives are found. Standard approaches for estimating PPVs 
(e.g., chart reviews) may not be effective for ascertaining false negatives due to outside use 
of health services.  Moreover, if both PPVs and NPVs are readily estimable by exposure in a 
study, then the validation study results could be used to estimate sensitivity and specificity.  




4.3.c. QBA using PPVs stratified by exposure, assuming non-differential outcome sensitivity  
 Brenner and Gefeller demonstrated that, given non-differential outcome sensitivity, 
the ratio of PPV1 to PPV0 is equivalent to the ratio of the true RR to the RR observed with 
misclassification(76).  Therefore, if the observed RR, PPV1, and PPV0  are known, then a 
corrected RR can be calculated (Formula 3). This method is a special case of the method in 
section 3.2, but the requirement of non-differential outcome sensitivity is a limitation.  As 
mentioned earlier, outcome false negatives may occur due to varying propensity of patients 
to seek care, or due to seeking care not captured in the database.  Depending on the study, 
such imperfect outcome sensitivity may be non-differential or differential to exposure. 
4.4          Simulation methods 
We conducted simulations of EHR-based cohort studies of early childhood 
immunization schedule safety to demonstrate these predictive value-based QBA methods. 
Simulations were nested within a cohort of children born 2002-2012 from two VSD sites, 
Kaiser Permanente Colorado and Kaiser Permanente Northern California.  Both health plans’ 
Institutional Review Boards approved this study. The cohort included n=257,010 children 
continuously enrolled in their health plan from birth to their 2nd birthday, which is when 
children are recommended to receive up to 28 vaccine doses per the U.S. recommended 
immunization schedule(1).  Follow-up time for these children was from their 2nd birthday to 
the first occurrence of either disenrollment from the health plan or their 8th birthday.  The 
only actual data used from this cohort were birthdates and this follow-up time; all other data 
in the study were simulated. 
Details of our simulation methods are described in Chapter 2. Briefly, we used 
probabilistic modeling to simulate that 2.4% of the cohort was exposed to alternative 
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immunization schedules and 60.6% received all vaccines on-time per the U.S. recommended 
immunization schedule (unexposed group)(117). The remaining 37.0% are assumed to be 
under-vaccinated by some other pattern (e.g., completely unvaccinated, missing some 
vaccines)(117); these patterns are not considered in our simulations. We simulated a baseline 
outcome rate of 1,000 events/100,000 person-years in ages 2 to 8 years and RRs of 2.00, 
1.00, and 0.50 across 1,000 replications.  These simulated RRs represent the true exposure-
outcome association, without misclassification bias. 
We then applied imperfect outcome specificity and sensitivity to the simulations 
based on overall outcome misclassification levels previously observed in electronic 
databases(14-16, 118, 119).  We simulated non-differential misclassification, where 
specificity and sensitivity were applied without regard to exposure, and differential 
misclassification, where these levels were applied separately by exposure group.  We 
simulated two scenarios of lower sensitivity among children on alternative schedules, since 
parents of these children express greater distrust in the traditional medical system and are 
more likely to seek outside care(87). We simulated scenarios of higher and lower specificity 
in the exposed group as compared to the unexposed. Sensitivity and specificity were applied 
to simulated data as probabilities, and Bernoulli trials determined which children had an 
outcome false positive or false negative status, representing outcome misclassification.   
For each combination of sensitivity and specificity tested, we reported the mean 
outcome PPV and NPV overall, PPV1 and NPV1, and PPV0 and NPV0 across the 1,000 
replications.  We reported the mean RR from analysis of electronic data when 
misclassification is present (Formula 1). We then applied Formulas 2 and 3 to the simulated 
data, and report the mean RR from each of these bias correction methods.  For simulations 
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where true RR=1, we reported Type 1 error as the percent of simulated replications where the 
null hypothesis was rejected at alpha=0.05. 
 All analyses were conducted in SAS® 9.4. 
4.5  Simulation results 
Across replications, there was an average of n=6,117 children simulated to be 
exposed to alternative immunization schedules and n=155,731 children simulated to the 
fully-vaccinated unexposed group.  Based on actual person-time in our cohort, there was an 
average of 8,207 outcomes in the unexposed group across replications, equating to a 5% 
baseline outcome prevalence.  With non-differential outcome misclassification and simulated 
RR=2.00, the outcome PPV among the exposed group (PPV1) is higher than the PPV among 
the unexposed group (PPV0) due to higher outcome prevalence among exposed (Table 13).  
In contrast, when simulated RR=0.50 and outcome misclassification is non-differential to 
exposure, PPV1 is lower than PPV0 (Table 14).   
 In the six misclassification scenarios we examined, the mean RRs observed with 
electronic data analysis, ignoring misclassification bias, ranged from 1.04 to 3.19 when true 
RR=2.00 and from 0.39 to 2.06 when true RR=0.50. Overall mean outcome PPVs ranged 
from 71.1% to 84.6%.  The QBA method with PPVs and NPVs stratified by exposure 
(Formula 2) resulted in perfect correction of misclassification bias in all simulations. 
Applying PPVs stratified by exposure and assuming non-differential sensitivity was also 
effective, except when outcome sensitivity was simulated to be differential (Tables 13 and 
14).  In some cases, applying this method when outcome sensitivity was differential by 
exposure resulted in more biased estimates than analysis of electronic data, ignoring 
misclassification bias.  For example, when true RR was simulated at 0.50, we observed 
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RR=0.39 when sensitivity among exposed was 50%, sensitivity among unexposed was 95%, 
and specificity in both groups was 99%.  After applying the ratio of PPV1 to PPV0 formula 
(Formula 4), the RR was 0.26 (Table 14). 
When simulated RR=1.00, non-differential outcome misclassification resulted in 
Type 1 error rates<5%.  However, in the four differential outcome misclassification 
scenarios, Type 1 error ranged from 80.7% to 100% (Table 15). The two methods with 
stratified outcome PPVs corrected the biased RR back to 1.00, except when sensitivity was 
differential to exposure and Formula 4, which assumes non-differential sensitivity, was used. 
4.6 Discussion 
Misclassification of clinical outcomes has garnered considerable attention in 
electronic database research, with calls for use of validated algorithms(11-13), increased 
transparency in data quality reporting(13, 120), and guidelines for the conduct and reporting 
of validation studies(9).  While these efforts affirm the importance of measuring 
misclassification in this line of research, there has been less emphasis on how to quantify and 
correct the bias caused by such misclassification.  In this paper, we reviewed QBA methods 
for outcome misclassification that are likely most accessible in electronic data-based 
pharmacoepidemiologic research: methods using only predictive values, applied to aggregate 
data.   
To date, results from validation studies have been considered in a largely qualitative 
manner, with high levels of sensitivity, specificity, or predictive values being interpreted as 
valid algorithms and acceptable for electronic data analysis.  However, epidemiologists have 
long warned that multiple factors influence how outcome misclassification biases an 
exposure-disease association(115), and that even small amounts of misclassification can 
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cause large amounts of bias(72).  Instead, if estimating an exposure-disease association is the 
end goal, then outcome validation from an internal sample of data should be approached with 
the goal of collecting the information necessary to conduct QBA.  If PPVs are being 
collected, these bias parameters should be stratified by exposure.   
Of the predictive value-based QBA methods reviewed, the method by Brenner and 
Gefeller is the most accessible, since it relies only on PPVs.  However, a limitation is the 
assumption of non-differential sensitivity. In their original paper, Brenner and Gefeller 
demonstrate that if sensitivity is differential, then the “corrected” RR from this method will 
still be biased by a factor of  
  
   
(76).  In practice, true sensitivity 
levels may be unknown, either overall or by exposure. If differential sensitivity is suspected, 
then the impact of plausible levels of difference in sensitivity on estimating the association 
between an exposure and an outcome could be tested by including this additional bias factor 
in bias analyses.   
The paucity of bias analysis reported in electronic data-based research(21), coupled 
with a pervasive emphasis on use of validated outcome algorithms, justified our focus on 
simple bias analysis for outcome misclassification.  However, QBA encompasses a field of 
methods, and extensions of simple bias analysis should be pursued in electronic data-based 
research(78). While epidemiologic studies using electronic databases are ideal candidates for 
bias analysis since sample sizes are typically large and random error is minimized(19), 
Bayesian and probabilistic bias methods that incorporate systematic and random error jointly, 
and allow for a range of bias parameters (in this case, PPVs or NPVs), should be utilized(19, 
21, 121). QBA methods accounting for multiple sources of systematic error, including 
exposure misclassification and unmeasured confounding, are also available(19). QBA 
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methods applied to individual-level data also merit broader consideration, including methods 
that treat outcome misclassification as a missing data problem(122). In addition, multiple 
strategies for bias analysis in multivariable modeling are available, including calculating bias 
parameters by stratum or using propensity scores to summarize information on the covariates 
in a bias analysis(123).   
Large data sources such as electronic health records and claims data have become 
cornerstones of modern pharmacoepidemiologic research.  Potential bias from 
misclassification of clinical outcomes in these data is a long-recognized problem with 
underappreciated solutions.  By providing an overview of methods for quantifying bias using 
outcome predictive values, we hope to encourage broader implementation of QBA in 
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Formula 1:  Calculation of relative risk observed in electronic data in an analysis of 




































Table 12:  Corrected distribution of outcomes by exposure using positive and negative 
predictive values stratified by exposure1 
 
 With Outcome 
 
Without Outcome 
Exposed  ∗ = (PPV1) +(1-NPV1) 
 
∗= (+) –((PPV1) + (1-NPV1)) 
 
Unexposed   ∗= (PPV0) + !(1-NPV0) 
 
!∗= ( +!) –( (PPV0) + !(1-NPV0)) 
 
1. Source:  Lash TL, Fox MP, Fink AK. Applying quantitative bias analysis to epidemiologic data. New York, 



































Formula 2:  Calculation of corrected relative risk following corrected distribution of 








































Formula 3:  Calculation of corrected relative risk using positive predictive values 
stratified by exposure, assuming non-differential sensitivity 
 




       
 
1. Source:  Brenner H, Gefeller O. Use of the positive predictive value to correct for disease misclassification in 
































Table 13:  Mean relative risk from electronic data analysis with outcome 
misclassification present and following quantitative bias analysis (QBA) using 
predictive values in a simulated immunization schedule cohort study with 1,000 
replications, when simulated risk ratio=2.001 









































































































































Table 13 continued: 
 



























































































1. Abbreviations:  PPV1= positive predictive value among exposed, PPV0= positive predictive value among 
unexposed, SN=overall outcome sensitivity, SP=overall outcome specificity, SN1=outcome sensitivity among 
exposed, SN0=outcome sensitivity among unexposed, SP1=outcome specificity among exposed, SP0 = outcome 















Table 14:  Mean relative risk from electronic data analysis with outcome 
misclassification present and following quantitative bias analysis (QBA) using 
predictive values in a simulated immunization schedule cohort study with 1,000 































































































     
  
SN1=95%; SN0=95% 






































Table 14 continued: 
 
1. Abbreviations:  PPV1= positive predictive value among exposed, PPV0= positive predictive value among 
unexposed, SN=overall outcome sensitivity, SP=overall outcome specificity, SN1=outcome sensitivity among 
exposed, SN0=outcome sensitivity among unexposed, SP1=outcome specificity among exposed, SP0 = outcome 


































































     
 
SN1=70%; SN0=95% 




































Table 15:  Mean relative risk from electronic data analysis with outcome 
misclassification present and following quantitative bias analysis (QBA) using 
predictive values in a simulated immunization schedule cohort study with 1,000 
replications, when simulated risk ratios=1.00 












































































































































































INTEGRATING QUANTITATIVE BIAS ANALYSIS FOR OUTCOME 
MISCLASSIFICATION IN ELECTRONIC HEALTH DATA-BASED RESEARCH 
5.1 Background 
Electronic health record (EHR) and medical insurance claims data, are becoming 
increasingly common in epidemiologic research(114, 124). These studies provide large 
cohorts with impressive statistical power, the ability to study rare outcomes, and the capacity 
to detect small, but sometimes clinically meaningful, exposure-disease associations.  
However, multiple threats to the validity of this research with electronic health data exist. In 
particular, outcome misclassification has received much scrutiny, with numerous validation 
studies documenting the sensitivity, specificity, positive predictive value (PPV), or negative 
predictive value (NPV) of algorithms for identifying a range of clinical outcomes within 
these data. However, even the best algorithms are typically imperfect, with the validation 
sample indicating that false positives or false negatives exist in the data.   
Since even small amounts of misclassification can cause large bias of an exposure-
outcome association(72), outcome false positives and false negatives in electronic data-based 
research are problematic. The burgeoning field of quantitative bias analysis (QBA) provides 
numerous methods for using estimates from validation studies to quantify, and ideally correct 
for, misclassification bias(19).  However, despite numerous calls for broader implementation 
of QBA(20, 125), and a published review of QBA methods for electronic data-based 
research(78), there has been minimal use of these methods(21). A key barrier to 
implementation of QBA has been a lack of practical instruction on how to incorporate these 
methods into studies(20).  Moreover, QBA was largely developed within studies with 
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prospective data collection. Currently, there is a lack of available guidance on implementing 
these methods within electronic data-based research.  
In this paper, our goal is to provide pragmatic guidance to addressing outcome 
misclassification bias in electronic health data-based research. We first describe the problem 
of outcome misclassification in this line of research, and demonstrate the impact of 
misclassification in a hypothetical example of a retrospective cohort study of immunization 
schedule exposure and risk of asthma.  Then, we review options for addressing outcome 
misclassification, ranging from conducting an electronic data only analysis to QBA methods.  
We demonstrate applications of these options within the immunization schedule-asthma 
study example.  Finally, we review additional considerations for applying QBA in electronic 
data-based research, including confounding adjustments, challenges with traditional 
validation methods, heterogeneity of outcome misclassification in multisite data networks, 
and implications for study designs other than the retrospective cohort. 
5.2 Outcome misclassification bias in electronic data-based research 
5.2.a. Outcome misclassification in electronic data 
 When using large electronic data sources for epidemiological studies, researchers 
typically apply an algorithm to the data to distinguish individuals with and without a clinical 
condition. Such algorithms may be simple, such as a single diagnosis code, or complex, 
incorporating multiple data elements such as diagnosis codes, procedure codes, and 
pharmacy dispensings(106). Other attributes, such as the timing, number, or clinical setting 
of these codes may also be considered(106). Outcome misclassification is present if the 
algorithm incorrectly classifies truly diseased individuals as not having the disease (false 
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negatives), or incorrectly classifies truly non-diseased individuals as having the disease (false 
positives; see Table 1 and Table 3 in Chapter 3). 
An algorithm is considered validated after it is compared against a gold standard for 
the clinical condition.  Sometimes, researchers can validate an algorithm against existing 
cohorts of individuals who have been previously confirmed as diseased and non-diseased, 
and report sensitivity and specificity estimates.  However, if existing diseased and non-
diseased cohorts are not available, then researchers may instead be able to estimate PPVs.  
To estimate a PPV, researchers take a sample of presumptive outcomes and distinguish true 
from false positives by reviewing medical provider notes or conducting patient surveys.  A 
PPV is then estimated as the percentage of the sample that are true positives. PPVs are the 
most commonly reported measures of algorithm validity in electronic health data-based 
research(13).  
While validation studies provide useful information as to the magnitude of 
misclassification itself, this information alone is insufficient for assessing error in the 
estimation of an exposure-outcome association.  Several factors influence how outcome 
misclassification causes systematic error of an exposure-outcome association. These factors 
include the magnitude of sensitivity and specificity, whether such sensitivity and specificity 
levels are the same or different by exposure,  baseline outcome prevalence, and true relative 
risk (RR)(115).  Systematic error results in bias in the estimation of an exposure-outcome 
association.  This is contrast to random error, which reflects the precision of the estimate(19). 
Electronic databases offer large cohorts for epidemiological research and random error is 
often minimal. While random error is routinely quantified in confidence intervals, systematic 
error is rarely quantified in electronic health data-based research(19). Instead, researchers 
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commonly use the discussion section of research papers to qualitatively assess the potential 
impact of any sources of bias(94). Often, it is assumed that any bias from outcome 
misclassification is either non-existent or inconsequential(20).  
5.2.b.  Example of misclassification bias in an immunization schedule-asthma study 
The hypothetical examples in Table 16 mimic an electronic health data-based 
retrospective cohort study of immunization schedule exposure and risk of asthma.  The 
CDC’s Vaccine Safety Datalink network is currently conducting observational studies of 
immunization schedule safety using EHR and claims data from integrated health plans 
nationwide, and asthma is one outcome of interest in these studies(8). In this hypothetical 
study, electronic vaccination records are used to identify 10,000 children vaccinated per 
alternative immunization schedules (exposed group) and 400,000 children vaccinated per the 
U.S. recommended immunization schedule (unexposed group).  We assumed a baseline 
outcome prevalence of 8.4%, which reflects national estimates for prevalence of pediatric 
asthma(126).  
 A previous validation study reported a sensitivity of 84.0% and specificity of 93.0% 
for identifying pediatric asthma in electronic health data(14). As shown in Example 2a, if the 
true RR is 2.00, and these levels of outcome sensitivity and specificity exist in the data 
source and are non-differential to exposure, then the RR observed in electronic data would be 
1.52 (95% confidence interval [CI] =1.47-1.58).  Misclassification bias would not affect the 
conclusion that individuals exposed to alternative immunization schedules have increased 
risk of asthma relative to children vaccinated per the recommended immunization schedule; 
however, the magnitude of the reported risk would be attenuated. 
87 
 
In contrast, in Example 2b there is no true association between immunization 
schedule exposure and asthma (RR=1.00).  However, outcome sensitivity is lower in the 
exposed group of children on alternative immunization schedules.  Previous studies have 
found that parents who chose alternative immunization schedules express more distrust in 
traditional medical systems and are also more likely to seek care from alternative medical 
providers, such as naturopaths(87). These different patterns of healthcare-seeking behavior 
could lead to lower outcome sensitivity in this group.  In Example 1b, outcome 
misclassification would lead to observing a RR of 0.94 (95% CI: 0.89 – 0.99), and 
misclassification bias would lead to a false conclusion that vaccinating per an alternative 
schedule offers a protective effect against asthma. 
5.3 Analytic options  
5.3.a. Analysis of electronic data, ignoring misclassification 
The Table 16 examples demonstrate that bias can occur when using a validated 
algorithm in electronic data, even if the outcome sensitivity and specificity estimates are 
“high”.  In Table 17, we provide options for confronting outcome misclassification bias in an 
electronic data-based study. The first option presented does not confront this problem, but 
does reflect what is typically done in electronic data-based research, which is to conduct an 
analysis of electronic data, ignoring outcome misclassification. In this approach, electronic 
data are analyzed as if all variables are perfectly measured. This is potentially problematic, 
since most validation studies have indicated that some misclassification of clinical outcomes 
exist in electronic health data(11, 119). There is only one scenario where outcome 
misclassification will not bias a risk ratio: when specificity is 100%, and sensitivity is non-
differential to exposure(86). In all other presentations of outcome misclassification, bias of a 
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ratio measure will occur, though the magnitude and direction of bias will vary based on 
several factors (sensitivity and specificity levels, whether the misclassification is non-
differential or differential to exposure, prevalence of outcome, and true RR)(115).   
5.3.b. Full validation approach 
In contrast, the full validation approach tries to circumvent outcome misclassification 
bias altogether(Table 17).  With this approach, the outcome status of all cohort members 
(both individuals observed to have the outcome and individuals observed to not have the 
outcome in EHR data) is reviewed and adjudicated through a structured process, such as a 
review of clinical provider notes. If the outcome status in electronic data is determined to be 
incorrect, then the data are updated and re-analyzed with the correct outcome status for all 
individuals.  While this approach, in theory, can eliminate misclassification bias, it is 
impractical for most large retrospective cohort studies, since reviewing all observed 
outcomes is time-consuming and expensive.  VSD studies have included cohorts of hundreds 
of thousands of children(5, 70); full validation of outcome status for such cohorts is not 
feasible.  Moreover, distinguishing true negative outcomes from false negative outcomes 
among individuals observed not to have the outcome in electronic health data is a challenge 
with standard validation approaches such as medical record reviews.  In many cases, primary 
data collection, such as a survey of parents, would be needed to ascertain whether a child 
who is observed not to have the outcome of interest in EHR data does in truth have the 
outcome. The full validation approach may be feasible with certain study designs, like case-
control and self-controlled case series methods, where the amount of data needed to conduct 




5.3.c. Quantitative bias analysis 
The last three methods presented in Table 17 involve conducting quantitative bias 
analysis (QBA).  The general approach of QBA for misclassification is to measure the extent 
of the misclassification in a study, and to then use such bias parameters to calculate the 
exposure-outcome association that would have been observed had such misclassification not 
been present(19). A key motivation for QBA is that qualitative assumptions as to the 
existence or magnitude of bias are often wrong(20, 95, 96). QBA does not refer to one 
specific analytic method, but rather a field of methods for quantifying systematic error in 
epidemiologic research(86, 113). 
Ideally, QBA is conducted with sensitivity and specificity estimates as bias 
parameters.  These estimates could either be obtained from a validation study conducted 
within the study of interest (an internal validation study) or using external data (an external 
validation study).  If non-differential misclassification is assumed, then the same outcome 
sensitivity and specificity estimates can be used in QBA formulas.  If differential 
misclassification is assumed, then separate sensitivity and specificity estimates by exposure 
are needed.   
A practical challenge to conducting QBA in electronic data-based research is that 
sensitivity and specificity estimates may not be readily available.  Instead, researchers can 
consider QBA using predictive values as bias parameters.  PPVs can be estimated by taking a 
sample of outcomes observed in electronic data and distinguishing true positives from false 
positives through a standard validation process, such as a review of clinical provider notes.  
NPVs are less readily estimable in electronic health data; however, QBA methods are 
available using only PPVs, and NPVs are not necessary if outcome sensitivity is non-
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differential to exposure(76). QBA using predictive values requires that such values are 
stratified by exposure. Furthermore, these QBA methods using predictive values should be 
reserved for bias parameters collected in an internal validation.  This is because predictive 
values are dependent on the prevalence of the outcome by exposure group, and even slight 
differences in prevalence across data sources and exposure groups can cause large 
differences in predictive values(111, 116). 
Finally, QBA can also be considered in electronic data-based research even if no a 
priori bias parameter estimates are available(113).  In this approach, the researcher estimates 
the amount of misclassification bias that would need to be present to change inference from 
the observed result.  The researcher then evaluates whether the levels of misclassification 
needed to change the observed results are plausible in the study population and data 
source(97, 113). This approach is important to consider in broader pharmacoepidemiologic 
research using claims data or other databases with no access to clinical provider notes, and no 
means of conducting a validation. This method provides a means of conducting a QBA even 
when no validation study estimates are available. 
 Numerous methods are available for implementing a quantitative bias analysis (Table 
18). A detailed review of these methods, including examples of their applications in 
published research, is available elsewhere(78).  Briefly, a starting point for incorporating 
QBA for outcome misclassification into an electronic health data-based study is a simple bias 
analysis.  With this method, either sensitivity and specificity estimates or predictive values 
are established as bias parameters, and mathematical formulas are used to calculate the 
relative risk that would have been observed had such misclassification not been present(19, 
72).  Probabilistic bias analysis is an extension of this method where a range of bias 
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parameters are considered.  A simulation approach is used, whereby bias parameters are 
sampled from this range multiple times, a bias analysis is conducted multiple times, and a 
range of corrected estimates is then reported(19). Bayesian bias analysis extends 
probabilistic bias analysis by also incorporating random error corrections in the QBA(121). 
Methods have been developed that apply multiple imputation methods for missing data to the 
problem of outcome misclassification, with the true value of the outcome being presumed to 
be missing for some or all individuals in a study(112, 122).  In addition, modified maximum 
likelihood methods are available where sensitivity and specificity are the input bias 
parameters, and an expectation-maximization algorithm is applied(127). 
5.3.d. Applications to the example immunization schedule-asthma study 
In Table 19, analytic options from Table 17 are applied to the hypothetical 
immunization-schedule asthma study examples from Table 16.  If an analysis of electronic 
data, ignoring outcome misclassification is conducted, then biased risk estimates are reported 
for these examples.  For Example 2b, this approach would mean that a false protective effect 
of vaccinating per an alternative immunization schedule would be reported.  This conclusion 
may lead to public concern and unnecessary policy changes. However, a full data validation 
is not a feasible solution for avoiding such bias, since, in both examples, the outcome status 
of 410,000 children would need to be confirmed.  An alternative study design, such as a case-
control study, could be considered, with full validation of outcome status for case and 
controls.  As reported in Table 19, a minimum of 521 cases and 2,082 controls would need to 
be validated to achieve 80% statistical power for this immunization schedule-asthma study.  
 Alternatively, several QBA options can be considered (Table 18).  If sensitivity and 
specificity are known, then QBA formulas using these estimates can be applied to correct the 
92 
 
biased RR (Appendix F).  As shown in Appendix G, simple bias analysis using sensitivity 
and specificity are effective in correcting the biased RR back to the true RR.  For Example 
2a, the RR was corrected back to 2.00 and for Example 2b, the RR was corrected back to 
1.00.  We also demonstrated QBA using predictive values as bias parameters (Appendix H). 
We applied two simple bias analysis methods using predictive values: one that relies on PPV 
and NPV estimates stratified by exposure, and one that relies on PPV estimates stratified by 
exposure and assumes non-differential outcome sensitivity.  To obtain PPVs stratified by 
exposure, researchers would need to randomly sample observed outcomes from both exposed 
and unexposed individuals, apply an adjudication procedure (such as a chart review), and 
estimate outcome PPVs for both exposed and unexposed individuals. As shown in Appendix 
I, both methods were effective for correcting misclassification bias in Example 2a. However, 
in Example 2b, the method assuming non-differential outcome sensitivity was ineffective, 
since outcome sensitivity was in fact different by exposure group. In this example, outcome 
sensitivity was lower among the undervaccinated group; this lower sensitivity would lead to 
this group looking like they have fewer outcomes than they actually do.  The QBA method 
that relies on PPVs alone does not inherently account for differing rates of outcome 
sensitivity by exposure. 
Finally, we demonstrated QBA with no a priori bias parameters estimates (Appendix 
J).  For this approach, we described how questions regarding the nature of misclassification 
bias can be posed, and how to evaluate the likelihood of different directions of 
misclassification.  We also demonstrate use a publicly-available interactive tool (available 
from the authors of a textbook on quantitative bias analysis(19)) to test the effects of 
different presentations of misclassification bias.  As described in Appendix J, for Example 2a 
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we can determine that the misclassification bias likely caused an attenuation of the true RR.  
However, for Example 2b (where outcome sensitivity is lower in the group of children 
exposed to alternative immunization schedules), we have insufficient information to 
determine whether bias is toward or away from the null.  Therefore, a validation study where 
bias parameters are collected or a different study design whereby outcome status can be 
validated for all individuals is advised. 
5.4 Additional considerations for addressing outcome misclassification bias 
 The QBA methods described in Tables 17 and 18, and applied to the immunization 
schedule-asthma example in Table 16, have operated under several assumptions.  First, these 
methods have been applied within unadjusted exposure-outcome associations, and have not 
considered adjustment for covariates.  Second, most of the approaches assume that bias 
parameters can be readily measured through standard methods, such as reviews of clinical 
provider notes or patient surveys.  Third, these methods assume that bias parameters are 
uniform throughout all data in a study, and do not consider that in a multisite electronic data-
based research, levels of misclassification could vary by study site.  In this section, these 
additional considerations are reviewed, and we also further elaborate on how study designs 
other than the retrospective cohort should be considered for addressing outcome 
misclassification bias. 
5.4.a. Strategies for multivariable analyses 
 In practice, bias analysis will often be conducted for exposure-outcome associations 
adjusted for multiple covariates. There are several strategies that can be used for conducting 
QBA for a multivariable model.  One strategy is to conduct a QBA for every covariate 
stratum, and then summarize the results over all strata(123). While this approach is relatively 
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straightforward, it will become cumbersome as the number of covariates in a model 
increases, since bias parameters will need to be collected for every stratum.  For 
multivariable models with many covariates, using propensity scores to summarize covariate 
information may be instead considered.  Propensity score methods have become popular in 
electronic health data-based research, since information on many covariates can be readily 
obtained from these data(128).  For bias analysis, propensity scores summarizing an 
individual’s risk of exposure given multiple covariates can be calculated and then later 
applied to the misclassification bias-adjusted exposure-outcome model(123).  Finally, 
another QBA approach for multivariable analyses involves calculating a “bias factor” that 
contains information on the magnitude and direction of bias caused by misclassification in 
the unadjusted exposure-outcome association, and then applying that factor to the adjusted 
exposure-outcome association(129). This approach assumes that the misclassification is 
unaffected by the covariates in the adjusted model. 
5.4.b. Issues with standard validation methods 
In electronic health data-based research, validation of outcome status is sometimes 
achieved by comparing the performance of an electronic data algorithm against existing, 
known diseased or non-diseased cohorts and estimating the algorithm’s sensitivity and 
specificity.  More commonly, a sample of presumptive outcomes is selected from the data, 
researchers use a review of clinical provider notes to distinguish true positives from false 
positives, and a PPV is calculated as the number of true positives divided by the entire 
sampled size.  A barrier in this approach is that sometimes clinical provider notes are 




In response to this problem, some electronic health data-based research studies have 
reported “confirmation rates”, indicating the percentage of presumptive outcomes that could 
be confirmed in the validation(107). In practice, presumptive outcomes observed in 
electronic health data fall into three categories following a validation: true positives, false 
positives, or unknown.  A confirmation rate represents the percentage of the sample 
confirmed as true positives.  Depending on the number of sampled observed outcomes that 
fall into the unknown category, this confirmation rate may closely reflect the true PPV, or 
may be very different than the true PPV.  Rather than estimating a confirmation rate, 
probabilistic bias methods can be useful for addressing this unknown category.  For example, 
if conducting a bias analysis using predictive values, researchers could estimate the ratio of 
true positives from all observed positives as their median PPV (this is the confirmation rate), 
but then establish a range of PPVs assuming that all sampled observed outcomes classified as 
“unknown” status are all true positives or false positives.  By sampling from within this range 
using probabilistic bias analysis, the additional uncertainty from the sample that could not be 
confirmed as a true or false positive is incorporated in the reported bias-corrected estimates. 
5.4.c. Heterogeneity of misclassification across data-contributing sites 
It is common for multiple health systems to collaborate in multisite electronic health 
record-based research.  In these networks, different study sites from across the U.S., and even 
internationally, prepare clinical, claims, and administrative data and compile them for use in 
epidemiologic research.  For example, in the U.S. both the CDC’s Vaccine Safety Datalink 
and the FDA’s Sentinel comprise of multiple study sites that share data to conduct vaccine 
safety research(29, 105). Data heterogeneity has been previously reported on in multisite 
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research networks(130), which raises a practical consideration that the underlying nature of 
data misclassification may also vary by site.  
There are several reasons why data misclassification may differ by site. For example, 
different provider behaviors across the country may lead to different coding practices, which 
may cause different outcome sensitivity and specificity rates across sites.  Different 
structures of the health systems participating in multisite research can also contribute to 
varying misclassification levels; for example, some patients may be more or less likely to 
seek care outside their health system depending on the types of services, like after-hours care 
or walk-up immunization clinics, offered by their health system. 
To date, there has been very limited evaluation of site-to-site variability in data 
misclassification, and on whether validation results from one site can be generalizable to 
another site(12). For some studies, estimating outcome misclassification and conducting a 
bias analysis may be feasible, following by a pooling or meta-analysis of results across sites.  
At minimum, multisite research networks conducting a multisite validation should seek to 
include all data-contributing sites in the validation, and to weight validation results based on 
the relative size of each site in the study of interest. 
5.4.d. Alternative study designs 
 In Table 19, we pointed out that while a full outcome validation on 410,000 children 
would not be feasible, full validation may be feasible if a different study design, such as a 
case-control design, is used.  If a researcher intends to analyze electronic health data as is, 
and not conduct any validation, then case-control designs provide few benefits relative to a 
retrospective cohort design.  However, these designs may be beneficial if eliminating 
outcome misclassification is a goal of the study, since all cases and controls could be 
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validated.  A similar design, the self-controlled case series design, has been commonly used 
for studies of individual vaccines and acute adverse events(36).  In these case-only studies, 
all observed outcomes can be validated, and data re-analyzed with only confirmed outcomes. 
 While designs other than the retrospective cohort may be promising for dealing with 
outcome misclassification bias, there are trade-offs to consider.  While a retrospective cohort 
study is ideal for studying rare exposures or multiple exposures, case-control studies offer the 
most statistical power when exposures are common. Self-controlled case series designs are 
well-suited for studies of acute adverse events, and are not practical for chronic outcomes or 
outcomes with insidious onsets.  Moreover, adjudication of outcomes observed in risk and 
control periods in this method may address the problem of outcome false positives in 
electronic data, but does not address outcome false negatives. 
5.5. Discussion 
The bias caused by data misclassification has been well-studied by epidemiologists, 
and analytic solutions to quantify this bias were developed several decades ago (20, 72, 115). 
However, a barrier to applying these solutions has been a lack of practical guidance on how 
to use such quantitative bias methods(20). This barrier is especially pronounced in electronic 
health data-based research, where the problem of outcome misclassification has been broadly 
studied(12, 13, 106), though applications of analytic solutions for this problem are currently 
lacking(21).  In this paper, we provided pragmatic guidance for integrating QBA for outcome 
misclassification in electronic health data-based research.   
By introducing researchers to various options for addressing outcome 
misclassification bias, applying these options to worked examples, and reviewing additional 
considerations, we hope this paper provides practical guidance for researchers on how to 
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quantify the impact of outcome misclassification bias in epidemiological research using 
electronic health data.  
 Multiple methods for conducting a QBA are available, and a review of these methods 
has been previously published(78). We provided guidelines on how to choose an appropriate 
method based on the bias parameters available to the researcher. The types of bias parameters 
available, or the availability of bias parameters at all, will steer the types of QBA methods 
available to the researcher. To our knowledge, this manuscript is the first to provide guidance 
on choosing a bias analysis method for electronic health data-based research based on the 
bias parameters available. 
 The use of electronic health record, claims, and administrative data for epidemiologic 
research has increased at a rapid pace in recent decades.  However, this field of research has 
been criticized for lacking an epidemiologic foundation, including a lack of assurances that 
valid inferences can be made using these data sources(114, 131). By pursuing methods to 
identify and quantify biases in studies using these data, researchers can meet the growing 















Table 16:  Hypothetical examples of outcome misclassification bias caused by 
misclassification of asthma status1,2 
Example 2a: 
Step 1: Show true exposure-outcome association 
 With outcome Without 
outcome 
Exposed 1,680 8,320 
Unexposed 33,600 366,400 
True Relative Risk:  2.00 (95% CI: 1.91 – 2.09) 
 
Step 2: Apply levels of misclassification: 
SNexposed = 84.0% 
SNunexposed = 84.0% 
SPexposed = 93.0% 
SPunexposed   = 93.0% 
Overall SN = 84.0% 
Overall SP = 93.0% 
 
Step 3: Show observed exposure-outcome association, with misclassification 
 With outcome Without 
outcome 
Exposed 2,010 7,990 
Unexposed 54,208 345,792 
Observed Relative Risk: 1.48 (95% CI:  1.43 – 1.54) 
 
Step 4:  Report consequence of misclassification 
Bias toward the null 
Example 2b: 
 
Step 1: Show true exposure-outcome association 
 With outcome Without 
outcome 
Exposed 840 9,160 
Unexposed 33,600 366,400 
True Relative Risk:  1.00 (95% CI: 0.94 – 1.07) 
 
Step 2: Apply levels of misclassification: 
SNexposed = 75.0% 
SNunexposed = 84.0% 
SPexposed = 93.0% 
SPunexposed   = 93.0% 
Overall SN = 84.7% 
Overall SP = 93.0% 
 
Step 3: Show observed exposure-outcome association, with misclassification 
 With outcome Without 
outcome 
Exposed 1,271 8,729 
Unexposed 54,208 345,792 
Observed Relative Risk: 0.94 (95% CI: 0.89 – 0.99) 
 
Step 4:  Report consequence of misclassification 
Type 1 error 
1. Abbreviations: SN=sensitivity, SP=specificity, CI=confidence interval 
2. In a hypothetical cohort study of 10,000 exposed individuals, 400,000 unexposed individuals, and a baseline 
outcome prevalence of 8.4%. 
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Strengths Limitations & Additional 
Considerations 
Analysis of electronic data, ignoring 
misclassification 
 
Electronic health record or claims data 
are analyzed as is, and any 
mismeasurement of outcome status is 
ignored.  A previously validated 
algorithm for identifying the outcome 
may or may not be used. The potential 
for misclassification bias may or may 
not be considered. 
 
 
- Easy to implement - This method assumes no outcome 
misclassification bias.  If 
misclassification is present, then 
estimates of the exposure-outcome 
association may be biased, potentially 
leading to incorrect conclusions. 
 
- Qualitative assumptions as to the 
presence of bias can be wrong. 
 
- Missed opportunity to quantify the 
magnitude and direction of bias if a 
validated algorithm was used. 
 
Full data validation 
 
A process to validate outcome status for 
all individuals in the study is 
established. Validation methods may 
include review of medical provider 
notes or patient surveys. All 
electronically-identified outcomes are 
adjudicated as either true or false 
positives. All electronically-identified 
non-outcomes are adjudicated to be true 
negatives or false negatives. Data are 
re-analyzed with correct outcome status 
for all individuals in study. 
 
- If all outcomes for individuals in 
the study can be validated, and 
analysis is conducted with the 
correct outcome status, then 




- Resource-intensive and expensive. 
Not practical for most large 
retrospective cohort designs.  May be 
feasible for other study designs, like a 
case-control or self-controlled case 
series. 
 
- For retrospectively-collected data, 
complete adjudication may not be 
possible.  For example, provider notes 
may not be available or may be 
unclear, or patients and families may 
not be able to accurately recall events.   
 
Quantitative bias analysis (QBA) with 
sensitivity (SN) and specificity (SP) as 
bias parameters 
 
Conduct an analysis of electronic health 
data. Then, quantify the magnitude and 
direction of bias based on outcome SN 
and SP estimates.  Report bias-corrected 
estimates.  
- Misclassification bias is 
quantified, and bias-corrected 
estimates are presented. 
 
- Multiple QBA methods are 
available (Table 3a). Both non-
differential and differential 
misclassification can be addressed. 
 
- Can be applied using SN and SP 
estimates from an internal validation 
sample, or from external data.  
 
 
- SN and SP estimates may be 
unknown and not readily estimable. 
 
- Involves additional analytic work 
beyond analysis of electronic health 

















Strengths Limitations & Additional 
Considerations 
Quantitative bias analysis (QBA) with 
sensitivity (SN) and specificity (SP) as 
bias parameters (continued) 
 
- Probabilistic bias methods allow for 
additional uncertainty in 
measurement of the bias parameters 




QBA with predictive values as bias 
parameters 
 
Conduct an analysis of electronic health 
data. Then, quantify the magnitude and 
direction of bias based on positive 
predictive value (PPV) and negative 
predictive value (NPV) estimates.  
Report bias-corrected estimates. 
 
- Misclassification bias is quantified, 
and bias-corrected estimates are 
presented. 
 
- Multiple QBA methods are 
available, including methods that 
rely only on PPVs. Both non-
differential and differential 
misclassification can be addressed. 
 
- PPVs are the most commonly 
reported measure of misclassification 
reported in electronic health data-
based research.   
 
- PPVs must be estimated by 
exposure.  This involves sampling 
observed outcomes from each 
exposure stratum, and calculating 
PPVs for each exposure stratum 
following outcome adjudication. 
 
- Estimation of negative predictive 
values may not be feasible. 
 
- Involves additional analytic work 
beyond analysis of electronic health 
data as is. 
 
 
QBA with no a priori bias parameter 
estimates 
 
Conduct an analysis of electronic health 
data. Then, quantify the robustness of 
electronic data-only analysis under 
plausible levels of outcome 
misclassification.  For example, 
determine the levels of outcome SN and 
SP that would impact the exposure-
outcome association such that the 
conclusion of the presence of absence of 
such association would change. Then, 
determine whether such SN and SP 
levels are plausible.  
 
 - Can be conducted for any study.  
 
- Multiple QBA methods are 
available.  Both non-differential and 
differential misclassification can be 
addressed. Probabilistic bias methods 
are most applicable, since a range of 
bias parameters can be considered. 
- Involves additional analytic work 
beyond analysis of electronic health 
data as is. 
 
- Plausible levels of outcome 














Table 18:  Examples of methods for quantitative bias analysis for outcome 
misclassification1 
Method Brief Description & References 
 
Simple bias analysis  Sensitivity and specificity estimates, or positive and negative predictive 
value estimates, are applied to observed, aggregate exposure-disease 
summary data.  Then, quantitative bias analysis formulas are used to 
calculate the aggregate exposure-disease summary estimates and relative 
risk that would have been observed had the misclassification not been 
present(19). If predictive values are used as bias parameters, then these 
estimates must be stratified by exposure, regardless of whether the 
underlying misclassification is non-differential or differential to 
exposure(19, 76). If sensitivity and specificity estimates are used as bias 
parameters, and outcome misclassification is non-differential to exposure, 





As an extension of simple bias analysis, this approach allows for additional 
uncertainty in the estimation of the bias parameters themselves to be 
considered in the quantitative bias analysis.  Rather than assuming known 
values for the bias parameters, a range of bias parameters is instead 
considered. A probability distribution is established for this range, bias 
parameters are sampled multiple times, and the quantitative bias analysis is 





This method is an extension of probabilistic bias analysis, where the 
probability distribution of bias parameters is considered as the prior 
distribution in a Bayesian analysis, and both corrections for random error 





With these methods, the true value of the outcome is considered as a 
missing data problem.  These methods rely on having sensitivity and 
specificity estimates(122).  Extensions of this work include using 






This approach uses observed data from the entire study and sensitivity and 
specificity from an internal validation sample to form the modified 
maximum likelihood function. Then, maximized likelihood estimates can 
be obtained through an expectation-maximization algorithm using the 
modified maximum likelihood(127). 
 
1. A detailed overview of many of these methods, and references to studies where these methods have been 
used, is available in Jonsson-Funk M and Landi SN. Misclassification in administrative claims data: quantifying 




Table 19:  Analytic options for outcome misclassification, applied to immunization 
schedule-asthma study examples from Table 2 
Analytic option 
 
Application to Example 2a in Table 
16, True Relative Risk (RR) = 2.00 
 
Application to Example 2b in Table 
16, True Relative Risk (RR) = 1.00 




Although the true RR is 2.00, non-
differential outcome misclassification 
would lead to researchers reporting a 
RR of 1.52.  Since random error in 
this study is small (the observed 95% 
confidence interval is 1.47 – 1.58), 




Differential outcome sensitivity 
would lead to a rejection of the null 
hypothesis with an observed RR of 
0.94 (95% CI: 0.89 – 0.99) and Type 
1 error.  Researchers may conclude 
that being vaccinated per an 
alternative immunization schedule 
offers protective benefits from 




Full data validation 
 
 
Full validation of the cohort would 
involve adjudicating the outcome 
status of 56,218 children observed to 
have asthma and 353,782 children 
observed not have asthma in 
electronic data.  Full validation would 
be expensive and likely take years of 
primary data collection, either 
through reviews of medical records or 
patient surveys.  
 
 
Full validation of the cohort would 
involve adjudicating the outcome 
status of 55,479 children observed to 
have asthma and 354,521 observed 
not have asthma in electronic data.  
Such full validation would be 
expensive and likely take years of 
primary data collection, either 
through reviews of medical records or 
patient surveys.  
Full data validation using a different study design: Instead of using a cohort 
design, researchers could implement a case-control design and conduct a full 
validation of asthma cases and controls identified in electronic data.  If the 
researchers assumed a 1:4 case-control ratio, 2.4% exposure prevalence in 
controls, and a detectable odds ratio of 2.0, then a minimum of 521 cases and 
2,082 controls would need to be validated for 80% statistical power.1 
 
Quantitative bias analysis QBA) with 
sensitivity (SN) and specificity (SP) as 
bias parameters 
  
Simple bias analysis: 
Formulas for simple bias analysis 
with non-differential and differential 
misclassification are available in 
Appendix F.  In Appendix G, these 
formulas are applied to Examples 2a 
and 2b from Table 16.  After applying 
the formula, the corrected RR is 2.00.  
In practice, to use this method the 
exact SN and SP values would have 
to be known, and it would also have 
to be known that the outcome 
misclassification is non-differential to 
exposure. 
 
Simple bias analysis: 
After applying the simple bias 
analysis formula for differential 
misclassification (Appendix F), the 
corrected RR is 1.00 (Appendix G).  
In practice, to use this method the 
exact SN and SP values need to be 















Application to Example 2a in Table 
16, True Relative Risk = 2.00 
 
Application to Example 2b in Table 
16, True Relative Risk = 1.00 
QBA with predictive values as bias 
parameters 
Formulas for two methods for QBA 
using predictive values are shown in 
Appendix H.  One method involves 
applying positive and negative 
predictive values (PPVs and NPVs) 
stratified by exposure to observed 
exposure-disease counts; the other 
methods involves knowing the PPVs 
stratified by exposure, and assumes 
non-differential outcome sensitivity. In 
this example, both methods effectively 
corrected the RR to 2.00 (Appendix I).   
Note that while PPVs are readily 
estimable in electronic data-based 
research, NPVs are more challenging 
to ascertain.   
 
 
The method applying PPVs and NPVs 
stratified by exposure was effective in 
correcting the RR back to 1.00 
(Appendix I). However, the method of 
multiplying the observed RR by the 
ratio of the PPV in the exposed to the 
PPV in the unexposed was not 
effective, since, in this example, 
outcome sensitivity was differential to 
exposure.  
QBA with no a priori bias parameter 
estimates 
 
The process for conducting this type of 
QBA is described in detail in 
Appendix J.  Briefly, both conditions 
that would have caused an attenuation 
of the true effect, or the observation of 
a positive exposure effect when no 
exposure effect truly exists are 
considered.  Quantitative bias formulas 
programmed into Excel® spreadsheets 
are used to investigate various 
presentations of misclassification.  We 
conclude that, given known 
information on the nature of outcome 
sensitivity between the exposed and 
unexposed groups, an attenuation of a 
true exposure effect due to 
misclassification bias is likely. 
 
The process for conducting this type of 
QBA is described in detail in 
Appendix J.  Briefly, both conditions 
that would have caused an attenuation 
of the true effect, or the observation of 
a protective exposure effect when no 
exposure effect truly exists are 
considered.  Excel® spreadsheets are 
used to investigate various 
presentations of misclassification.  We 
conclude that either scenario – a bias 
toward the null, or a bias away from 
the null – is plausible given known 
information about presentations of 
outcome misclassification in the data 
source.  Therefore, it is advisable to 
conduct a validation study to collect 
bias parameters and conduct one of the 
QBA methods described above, or to 
conduct another study where outcome 
misclassification is eliminated or 
minimized.  For example, a different 
study design where the outcome status 
of all individuals is adjudicated may be 
considered. 
 
1. Case-control sample size calculations were conducted using OpenEpi, Sample Size Calculation for an 
Unmatched Case-control study. Available at http://www.openepi.com/SampleSize/SSCC.htm.  Accessed on 
December 8, 2017.  The reported results are using the method from Kelsey et al., Methods in Observational 








6.1 Summary of findings 
 This dissertation is an original scholarly contribution focused on a methodological 
issue in research using electronic health record and medical claims data: misclassification of 
outcome status. To date, most research on this problem has centered on quantifying the 
misclassification itself, without in-depth consideration of how such misclassification causes 
bias of an exposure-outcome association.  In the work presented in this dissertation, I have 
linked outcome misclassification in electronic health data-based research to the bias of an 
exposure-outcome association that this misclassification causes. Furthermore, I have 
demonstrated that analytic strategies from the field of quantitative bias analysis are effective 
for quantifying and correcting such outcome misclassification bias in simulations of 
immunization schedule safety studies. 
 The key findings from this dissertation work, by study aim, are: 
Aim 1a: Outcome positive predictive values (PPVs) are not effective indicators of 
outcome misclassification bias. This finding contradicts previous assertions that outcome 
PPVs greater than 70% are sufficient for analysis of electronic data(11). 
Aim 1b: Traditional methods for quantitative bias analysis (QBA) using sensitivity 
and specificity estimates as bias parameters are effective for correcting outcome 
misclassification bias. Using simulations, I demonstrated that these methods corrected risk 
ratio estimated to within 5% of the true risk ratio (Hypothesis 1). For this aim, I demonstrate 
the applicability of QBA in immunization schedule safety research; however, a key limitation 
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of using traditional QBA methods is that sensitivity and specificity estimates are not always 
available in electronic health record-based research. 
Aim 2: Two predictive value-based methods for correcting bias of a risk ratio due to 
outcome misclassification are effective in correcting misclassification bias across different 
scenarios of misclassification. If PPVs and NPVs stratified by exposure are known, then bias 
of a risk ratio can be perfectly corrected in all scenarios of misclassification (Hypothesis 2). 
A method requiring only PPVs stratified by exposure is also effective in scenarios when 
outcome sensitivity is non-differential to exposure. A key finding from this aim was that for 
PPVs to be effective for bias correction, these metrics must be estimated by exposure, which 
is a departure from current practices in electronic health data-based validation studies.  
Aim 3:  Guidelines for integrating quantitative bias analysis for outcome 
misclassification within electronic health record-based immunization schedule safety 
research can facilitate uptake of these methods.  I outlined a systematic approach for 
confronting the problem of misclassification bias in this line of research.  Using an example 
of an electronic health data-based study of immunization schedule exposure, I demonstrated 
three methods for quantitative bias analysis based on the type of bias parameters available to 
the researcher.   
I accomplished the work in this dissertation by bringing together two disparate 
streams of research. One stream of research has focused on validation of clinical outcomes in 
electronic health data, including electronic health record and medical claims data. That line 
of work has focused on estimating the sensitivity, specificity, positive predictive value, or 
negative predictive value for algorithms for identifying clinical outcomes in such electronic 
health data sources.  In these validation studies, outcomes with high values for these metrics 
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are considered valid, though no thresholds had been empirically established where lack of 
misclassification bias is guaranteed (except when all misclassification metrics are 100%, 
indicating no data misclassification). After validating an algorithm, researchers typically 
proceed with analyzing electronic data as is, even if the validation study indicated that some 
outcome misclassification does exist.  However, a second stream of research has focused on 
epidemiological investigations of misclassification and its bias. This stream of research has 
been pursued by epidemiologists for decades, and has demonstrated that even small amounts 
of misclassification can cause large amounts of bias(72). This work was further pursued with 
the development of analytic solutions for this problem, broadly referred to as quantitative 
bias analyses(19).  However, quantitative bias analyses have largely been conducted within 
prospective cohort studies, not large, retrospective cohort studies using electronic health data.  
With the work presented in this dissertation, I combined these two streams of research and 
demonstrated that validation studies alone are insufficient for guaranteeing lack of bias from 
outcome misclassification in electronic health data-based research. Instead, validation studies 
should be pursued with the goal of collecting the bias parameters needed to conduct a 
quantitative bias analysis.   
This dissertation work was conducted within the context of electronic health record-
based immunization schedule research; specifically, studies currently being led by Centers 
for Disease Control and Prevention’s Vaccine Safety Datalink (VSD). There are three 
reasons why these studies provide a fitting case example for the problem of and solutions for 
misclassification bias in electronic health data-based research. First, the problem of outcome 
misclassification in electronic health record- and medical claims-based research is already 
evident in vaccine safety research. VSD has invested substantial resources into outcome 
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adjudication for studies of individual vaccines and acute adverse events, and the Food and 
Drug Administration’s Sentinel program has also pursued outcome validation studies for its 
post-marketing vaccine safety surveillance. However, VSD’s efforts to adjudicate all 
outcomes (e.g. in its studies of acute adverse events) are not feasible for studies of 
immunization schedule exposure and common outcomes, so other solutions are needed. Of 
note, during the time of this dissertation work, the Sentinel program contracted with experts 
in the field of quantitative bias analysis to develop these methods for their vaccine safety 
work(113).  Second, VSD studies of immunization schedule are large, and random error will 
be minimal, making these studies ideal candidates for quantitative bias methods.  Third, 
vaccine safety studies receive a great deal of public scrutiny, and results from immunization 
schedule safety studies may have important policy implications. Therefore, it is important to 
proactively address sources of bias as part of the design and conduct of these studies. 
6.2. Dissemination and implementation 
 The work presented in this dissertation has already had an impact on the design and 
conduct of VSD studies. At different stages, I have presented this dissertation work at three 
national VSD meetings: the 2015 VSD Annual Meeting in Atlanta, GA, the 2016 VSD 
Immunization Schedule Methodology Meeting in Denver, CO, and the 2017 VSD Annual 
Meeting in Oakland, CA.  I believe that these presentations and my continued collaborations 
on VSD work are leading to more informed decisions on how to approach the problem of 
misclassification and its bias in VSD.  For example, on VSD studies I am currently working 
on, we now develop and integrate plans for quantitative bias analysis as part of the study 
design process.   
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 I have also disseminated this work outside of VSD.  Chapter 3 was published in the 
journal Pharmacoepidemiology & Drug Safety in February 2018. Early work from that 
chapter was presented at the 2016 International Society for Pharmacoepidemiology Mid-Year 
Meeting. The work presented in Chapter 4 has also been submitted to and is under review at 
the journal Pharmacoepidemiology & Drug Safety, as part of a Validation Studies special 
issue. Early work from that chapter was presented at the 2017 Society for Epidemiologic 
Research meeting in Seattle, WA.  Based on that presentation, I received interest from other 
researchers on this work, which led to the development and acceptance of a symposium at the 
2018 Society for Epidemiologic Research Annual Meeting titled “Shaping the Future of 
Epidemiologic Research Using Electronic Healthcare Databases.”  I plan to submit portions 
of Chapter 5 as a methods paper focused on introducing quantitative bias analysis to a 
clinical research audience. 
6.3. Future directions 
 With this dissertation, I have organized a process for how to conceptualize and 
address misclassification bias in electronic health record-based immunization schedule safety 
research.  Using simulations, I demonstrated that given levels of outcome misclassification 
that have been previously measured in electronic health data, misclassification bias can occur 
in this line of research.  It is my hope that this work helps elucidate the problems stemming 
from outcome misclassification in electronic health record data, and provides researchers 
with the practical guidance necessary to incorporate quantitative bias analysis in 
immunization schedule safety research. 
I anticipate that more work is needed before quantitative bias analysis comes into 
widespread use, either in immunization schedule safety research specifically or in electronic 
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health data-based research more generally.  I see two future directions for the work presented 
in this dissertation. One direction is broader dissemination of quantitative bias methods and 
structured activities to accelerate implementation of these methods in electronic health data-
based research. Numerous methods have been developed for quantitative bias analysis, but 
these methods are primarily published in epidemiological and biostatistical literature, and by 
a limited number of individuals(21). These methods need to be presented to broader 
audiences involved in electronic health data-based research, including health services 
researchers and clinicians. Structured activities such as workshops or the development of 
online tools could also facilitate use of these methods. A second future direction for this work 
is developing effective approaches for communicating about uncertainty in research.  
Conducting a bias analysis for outcome misclassification involves acknowledging that data 
are measured imperfectly and that this problem can cause bias. To some audiences, such 
concepts may initially be difficult to understand. Some stakeholders of medical research will 
resist these acknowledgements and claim that such research is flawed, when, in truth, almost 
all medical research suffers from lingering uncertainty. To move toward broader use of 
analytic solutions for addressing bias, we will need to develop strategies for effectively 
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Recommended immunization schedule before age 2 years in the United States, 2017 
Vaccine Recommended Doses 
Before Age 24 Months  
Recommended Age at Receipt 
Hepatitis B Dose 1 At birth 
Dose 2   1-2 months 
Dose 3 6-18 months 
Rotavirus1 Dose 1 2 months 
Dose 2   4 months 
Dose 3 6 months 
Diphtheria, tetanus, and 
acellular pertussis 
Dose 1 2 months 
Dose 2   4 months 
Dose 3 6 months 




Dose 1 2 months 
Dose 2   4 months 
Dose 3 6 months 
Dose 4 12-15 months 
Pneumococcal 
conjugate vaccine 
Dose 1 2 months 
Dose 2   4 months 
Dose 3 6 months 








Age 24 Months  
Recommended Age at Receipt 
Inactivated poliovirus Dose 1 2 months 
Dose 2   4 months 
Dose 3 6-18 months 
Measles, mumps and rubella Dose 1 12-15 months 
Varicella Dose 1 12-15 months 
Hepatitis A3 Dose 1 12-23 months 
Dose 2   12-23 months 
Inactivated influenza vaccine4 Annual vaccination with 1 or 2 doses after age 6 
months*** 
 
1. Vaccination at age 6 months is not necessary for rotavirus if the child previously received two doses of the 
Rotarix (GlaxoSmithKline, Rixensart, Belgium) vaccine brand.   
2. Vaccination at age 6 months is not necessary for Haemophilus influenzae type b if the child previously 
received two doses of the PedvaxHib (Merck, Whitehouse Station, New Jersey, USA) vaccine brand. 
3.. For Hepatitis A, the two dose series should be initiated between ages 12 and 23 months and should be 
separated by a minimum of six months. 
4. Annual seasonal influenza vaccination is recommended for all children older than age 6 months.  In the U.S., 
influenza season typically spans from September to March.  Children should receive two doses of the influenza 
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Adolescents Aged 18 Years of Younger – United States, 2017.  MMWR – Morbidity and Mortality Weekly 









Changes to the U.S. pediatric immunization schedule, 1983 - 2017 
 
Timeline of major changes to the recommended U.S. immunization schedule for children less 
than age 24 months, 1983 - 2017 
 
 Year  Change to U.S. immunization schedule  
1983 Three vaccines are on the schedule:  diphtheria-tetanus-whole cell pertussis (DTP), 
oral poliovirus (OPV), and measles-mumps-rubella (MMR). 
1989 Vaccine for Haemophilus influenzae type b (Hib) is added to the schedule. 
1994 - 
1995 
Whole cell pertussis vaccine in DTP replaced with acellular pertussis vaccine; new 
vaccine is DTaP. 
Hepatitis B (HepB) vaccine added to schedule. 
1996 Varicella vaccine added to schedule. 
Combined Hib-HepB (Comvax®, Merck, Whitehouse Station, New Jersey, USA)  
vaccine approved for use in the U.S.  
1997 - 
1998 
Live OPV vaccine replaced with inactivated poliovirus vaccine (IPV). 
1999 Rotavirus vaccine added to schedule. 
2000 Rotavirus vaccine removed from schedule due to safety concerns. 
Hepatitis A (HepA) vaccine added to schedule, but recommended only for special 
populations. 
2001 Pneumococcal conjugate vaccine added to schedule.  
2002 Combined DTaP-IPV-HepB vaccine (Pediarix®, GlaxoSmithKline, Rixensart, 
Belgium) is approved for use in the U.S. 
2004 Seasonal influenza vaccine recommendations expanded to all children. 
2005 Combined MMR and varicella vaccine (ProQuad®, Merck, Whitehouse Station, New 
Jersey, USA) is approved for use in the U.S. 
2006 HepA vaccination recommendation expanded to include all children.  




APPENDIX B continued 
 
 Year  Change to U.S. immunization schedule  
2008 Combined DTaP-IPV-Hib vaccine (Pentacel®, Sanofi Pasteur, Stillwater, PA) is 
approved for use in the U.S. 
2017 As of the 2017 U.S. schedule, children are recommended to receive HepB, rotavirus, 
DTaP, Hib, pneumococcal, IPV, MMR, varicella, HepA, and seasonal influenza 
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Positive Predictive Value = 
 
 )*+,--.-/ 0 12*.34*+5*







Negative Predictive Value = 
 
 
 )*5-9-5-/ 0 (1 − 12*.34*+5*)

























E1 = exposed 
 
SN = overall outcome sensitivity   
E0 = unexposed 
 
SNE1 = outcome sensitivity among exposed  
D1 = diseased (with outcome) 
 
SNE0 = outcome sensitivity among unexposed 
 
 
D0 = non-diseased (without 
outcome) 
 
SP = overall outcome specificity   
EHR= electronic health record SPE1 = outcome specificity among exposed 
 
 
 SPE0 = outcome specificity among unexposed   
 
Aassuming non-differential outcome misclassification:   
 
Observed in EHR data  Corrected data 
 E1 E0  E1 E0 
D1 a b D1 A = [a - E1 Total (1- SP)] 
/ [(SN – (1- SP)] 
B = [b - E0 Total (1- SP)] / 
[(SN – (1- SP)] 
D0 c d D0 C = E1 Total  - A D = E0 Total  - B 




    
 
Assuming differential outcome misclassification:   
 
Observed in EHR data  Corrected data 
 E1 E0  E1 E0 
D1 a b D1 A = [a- E1 Total (1- 
SPE1)] / [(SNE1 – (1- 
SPE1)] 
B = [b- E0 Total (1- SPE0)] 
/ [(SNE0 – (1- SPE0)] 
D0 c d D0 C = E1 Total  - A D = E0 Total  - B 




    
 
Reference: Lash TL, Fox MP, Fink AK. Applying quantitative bias analysis to epidemiologic 





Positive predictive value examples 
Examples showing that an overall positive predictive value is not indicative of the presence, 
magnitude, or direction of outcome misclassification. In a hypothetical cohort study of 
10,000 exposed individuals, 400,000 unexposed individuals, and a baseline outcome 
prevalence of 2.5%. 
 
Abbreviations:  RR=relative risk; SN1 = sensitivity among exposed; SN0 = sensitivity among unexposed; SP1 
= specificity among exposed; SP0 = specificity among unexposed; PPV=positive predictive value; PPV1 






Correction of a relative risk with outcome sensitivity and specificity estimates 
Formulas for simple quantitative bias analysis for outcome misclassification, using 
sensitivity and specificity as bias parameters 
 
Observed data, given outcome misclassification: 
 With outcome Without outcome  
Exposed (E1) a b E1 Total = a + b 
Unexposed (E0) c d E0 Total = c + d 
 
Formula for corrected relative risk, assuming non-differential misclassification = 
 
[;  ( <=)∗> ?@A;B] / [(<E – ( <=)]
> ?@A;B
[G  ( <=)∗>




where SP= outcome specificity and SN = outcome sensitivity 
 
 
Formula for corrected relative risk, assuming differential misclassification = 
 
[;  ( <=)∗> ?@A;B] / [(<E – ( <=)]
> ?@A;B
[G  ( <=)∗>




where  SP1= outcome specificity among exposed, 
SP0= outcome specificity among unexposed, 
SN1= outcome sensitivity among exposed, and 















Example of correction of relative risk with outcome sensitivity and specificity estimates 
Formulas for simple quantitative bias analysis using outcome sensitivity and specificity 
estimates (Appendix F), applied to Examples 2a and 2b from Table 16. 
 
Formulas applied to example 2a from Table 16: 
Observed data  
 With outcome Without outcome  
Exposed (E1) 2010 7990 E1 Total = 10000 
Unexposed (E0) 54208 345792 E0 Total = 400000 
 
Corrected relative risk formula, applied to observed data  
































 = 2.00 
 
 
Formulas applied to example 2b from Table 16: 
Observed data  
 With outcome Without outcome  
Exposed (E1) 1271 8729 E1 Total = 10000 
Unexposed (E0) 54208 345792 E0 Total = 400000 
 
Corrected relative risk formula, applied to observed data from Example 2b, Table 2: 










































Correction of a relative risk with outcome predictive values 
 
Observed data, given outcome misclassification: 
 With outcome Without outcome  
Exposed (E1) a b E1 Total = a + b 
Unexposed (E0) c d E0 Total = c + d 
 
 
Formula for corrected relative risk, using positive predictive values (PPVs) and 
negative predictive values (NPVs), stratified by exposure: 
Source: Lash TL, Fox MP, Fink AK. Applying quantitative bias analysis to epidemiologic 
data.Springer Science & Business Media; 2011. 
 
 











Formula for corrected relative risk, using PPVs stratified by exposure and assuming 
non-differential outcome sensitivity   
Source:  Brenner H, Gefeller O. Use of the positive predictive value to correct for disease 




















Example of correction of a relative risk with outcome predictive values 
Formulas for simple quantitative bias analysis using from outcome positive predictive 
estimates (Appendix H), applied to Examples 2a and 2b from Table 16. 
 
Formulas applied to example 2a from Table 2: 
Observed data  
 With outcome Without outcome  
Exposed (E1) 2010 7990 E1 Total = 10000 
Unexposed (E0) 54208 345792 E0 Total = 400000 
 
Positive predictive values (PPVs) and negative predictive values (NPVs) 
PPV among exposed = PPV1 = 71.04% 
PPV among unexposed = PPV0 = 52.69% 
NPV among exposed = NPV1 = 96.85% 
NPV among unexposed = NPV0 = 98.50% 
 
Formula for corrected relative risk, using positive predictive values (PPVs) and 
negative predictive values (NPVs), stratified by exposure, applied to observed data: 




















 = 1.99 
 
Formula for corrected relative risk, using PPVs stratified by exposure and assuming 
non-differential outcome sensitivity 
 
Corrected RR = 1.48 x  
\.]^%
_`.ab%









APPENDIX I continued 
 
Formulas applied to example 2a from Table 2: 
 
Observed data from Example 2b, Table 2: 
 With outcome Without outcome  
Exposed (E1) 1271 8729 E1 Total = 10000 
Unexposed (E0) 54208 345792 E0 Total = 400000 
 
Positive predictive values (PPVs) and negative predictive values (NPV) 
PPV among exposed = PPV1 = 49.57% 
PPV among unexposed = PPV0 = 52.69% 
NPV among exposed = NPV1 = 97.59% 
NPV among unexposed = NPV0 = 98.54% 
 
Formula for corrected relative risk, using positive predictive values (PPVs) and 
negative predictive values (NPVs), stratified by exposure, applied to observed data: 















 = 1.00 
 
Formula for corrected relative risk, using PPVs stratified by exposure and assuming 
non-differential outcome sensitivity 
 
Corrected RR = 0.94 x  
^b._\%
_`.ab%
  = 0.88* 
 
*Since outcome sensitivity was differential by exposure in this example, this method for bias 











Bias analysis with no a priori parameter estimates 
Quantitative bias analysis with no a priori bias parameter estimates for outcome 
misclassification, applied to Examples 2a and 2b from Table 16. 
 
For this analysis, we used an interactive Excel spreadsheet tool provided by the authors of: 
Lash TL, Fox MP, Fink AK. Applying quantitative bias analysis to epidemiologic data. 
Springer Science & Business Media; 2011.  The spreadsheets are available online at 
https://sites.google.com/site/biasanalysis (Accessed on December 12, 2017). 
 
Application to example 2a from Table 16: 
In this example, the observed relative risk (RR) is 1.48.  To apply quantitative bias analysis 
with no a priori bias parameter estimates, one could ask two questions: 
Question 1: What presentations of outcome misclassification would have caused an 
attenuation of the true RR? 
Question 2:  What presentations of outcome misclassification would have caused an 
observation of a positive exposure effect if no such effect truly exists, or if a protective effect 
of exposure truly exists? 
Then, each question can be evaluated by considering various presentations of 
misclassification and specifying the conditions required to address each question.  Here, an 
evaluation for each question is described: 
Evaluation for question 1:  Any presentations of non-differential outcome specificity would 
have attenuated the true RR.  Also, a lower outcome sensitivity in the exposed versus the 
unexposed group would have led to a higher rate of false negatives in the exposed group and 
thus an attenuation of a true exposure effect.  Lower sensitivity among the exposed group 
could occur if parents of children on alternative immunization schedules are more likely to 
seek care for asthma for their children outside the integrated health plan contributing to the 
electronic data source.  This phenomenon has been previously described in the literature(5, 
87). Both of these presentations of misclassification – non-differential specificity and lower 











APPENDIX J continued 
 
Evaluation for question 2:   
Bias toward observing a positive effect may occur for three reasons: 

















APPENDIX J continued 
 
 














APPENDIX J continued 
 
C:  A combination of both lower specificity in the exposed group and lower sensitivity in the 
exposed group; for example: 
 
 
In this example of an immunization schedule-asthma study, there is no reason to suspect that 
specificity is differential by exposure, though it may be differential due to chance alone.  
There is no reason to suspect that outcome sensitivity is lower in the unexposed group; in 
fact, as outlined in our evaluation for Question 1, we suspect that outcome sensitivity is 
lower in the exposed group.  Therefore, given no a priori bias parameters, we would conclude 
that the observed effect is likely an attenuation of the true effect, though the magnitude of 







APPENDIX J continued 
 
Application to example 2b from Table 16: 
In this example, the observed relative risk (RR) is 0.94.  To apply quantitative bias analysis 
with no a priori bias parameter estimates, one could ask two questions: 
Question 1: What presentations of outcome misclassification would have caused an 
attenuation of a true protective effect of exposure? 
Question 2:  What presentations of outcome misclassification would have caused an 
observation of a protective exposure effect if no such effect truly exists, or if a positive effect 
of exposure truly exists? 
Then, each question can be evaluated by considering various presentations of 
misclassification and specifying the conditions required to address each question.  Here, an 
evaluation for each question is described: 
Evaluation for question 1: Non-differential outcome specificity would have attenuated the 
true RR.  Also, a lower outcome sensitivity in the unexposed versus the exposed group would 
have led to a higher rate of false negatives in the exposed group and thus an attenuation of a 
true exposure effect. While non-differential outcome specificity is plausible in our data 
source, a lower outcome sensitivity in the unexposed group is unlikely, for the reasons 




















APPENDIX J continued 
 
Evaluation for question 2:   
Bias toward observing a protective exposure effect may occur for three reasons: 

















APPENDIX J continued 
 



















APPENDIX J continued 
 
C:  A combination of both lower specificity in the unexposed group and lower sensitivity in 




Based on our evaluations of questions 1 and 2, we conclude that either an attenuation of a 
true effect, a Type 1 error, or the observation of a protective exposure effect when a positive 
exposure effect truly exists are all plausible.  Based on this quantitative bias analysis with no 
a priori bias parameter estimates, we would conclude that more information is needed before 
determining the presence, direction, or magnitude of misclassification bias.  Next steps may 
include conducting a validation study to collect bias parameters for conducting a quantitative 
bias analysis, or considering a different type of study design that would allow us to validate 
outcome status for all individuals in the study. 
 
 
